 
 
 
InSpace™ Clinical Investigational Plan  
 
Study Title:  A prospective, single blinded, multi -center, randomized, 
controlled , pivotal  study to assess the safety and effectiveness of 
the InSpace™  device for treatment of full thickness Massive 
Rotator Cuff T ears 
 
Version No : Version 4.0   
Version Date:  March 26 , 2018  
 
Study Device:               InSpace™ Device  
CIP NCT No.:  NCT024936 60CLD -OR-010 
Sponsor :                                 Ortho -Space Ltd.  
7 Halamish St. Caesarea,  
308890, Israel  
     
 
Sponsor’s Contact Person :  Heather Neill , VP Clinical Operations  
  
Confidentiality Statement:  
The information contained in this Clinical Investigational Plan is provided to you in 
confidence, f or review by you, your staff and an applicable regulatory authority or 
institutional review committee. I t is understood that this information may not be 
disclosed to any other party, in any form, without  prior authorization from Ortho -
Space Ltd ., except to  the extent necessary to obtain informed consent from the persons 
on whom the medical device may be used . 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 1 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 TABLE OF CONTENTS  
STUDY PROTOCOL SIGNATURE PAGE  ................................ ................................ ............ 4 
STUDY SYNOPSIS  ................................ ................................ ................................ .................... 5 
TABLE 1:  STUDY FLOWCHART AND FOLLOW -UP ASSESSMENTS  ........................ 7 
1 BACKGROUND INFORMATION  ................................ ................................ .................... 9 
1.1 Introduction  ................................ ................................ ................................ ................................ ...............  9 
1.2 Device Name and Intended Use  ................................ ................................ ................................ ...............  10 
1.3 Investigational Device  ................................ ................................ ................................ .............................  11 
1.4 Regulatory Status and Human Clinical Data  ................................ ................................ ...........................  13 
1.5 Mode of Action  ................................ ................................ ................................ ................................ ........  15 
2 OVERVIEW OF INVESTIGATIONAL PLAN  ................................ ............................. 16 
2.1 Objectives  ................................ ................................ ................................ ................................ ................  16 
2.1.1 Primary Objectives  ................................ ................................ ................................ ..........................  16 
2.1.2  Secondary Objectives  ................................ ................................ ................................ .......................  16 
2.2 Endpoints  ................................ ................................ ................................ ................................ .................  16 
2.2.1  Primary Composite Endpoint  ................................ ................................ ................................ ..........  16 
2.2.2  Secondary Endpoints  ................................ ................................ ................................ .......................  16 
2.2.3  Safety Assessment  ................................ ................................ ................................ ............................  17 
3 PROTOCOL  ................................ ................................ ................................ ....................... 17 
3.1 Study Design  ................................ ................................ ................................ ................................ ............  17 
3.2 Subject Recr uitment and Screening  ................................ ................................ ................................ .........  18 
3.3 Study Blinding  ................................ ................................ ................................ ................................ .........  19 
3.4 Study Duration and Follow -up ................................ ................................ ................................ ................  19 
3.5 Randomization  ................................ ................................ ................................ ................................ .........  19 
3.6 Selection of Subjects  ................................ ................................ ................................ ................................  19 
3.6.1  Inclusion Criteria  ................................ ................................ ................................ .............................  19 
3.6.2  Exclusion Criteria  ................................ ................................ ................................ ............................  21 
3.7 Early Withdrawal of Subjects  ................................ ................................ ................................ ..................  23 
3.7.1  When and How to Withdraw Subjects  ................................ ................................ ..............................  23 
3.7.2  Data Collection and Follow -up for Withdrawn Subjects  ................................ ................................ . 23 
3.7.3  Study Site Termination  ................................ ................................ ................................ .....................  23 
3.8 Prior and Concomitant Therapy  ................................ ................................ ................................ ...............  24 
3.9 Study  Interventions – Full Thickness MRCT  ................................ ................................ ..........................  24 
3.9.1  Clinical and Functional Assessments  ................................ ................................ ..............................  24 
3.9.2  Magnetic Resonance Imaging (MRI)  ................................ ................................ ...............................  25 
3.9.3  Ultrasound  ................................ ................................ ................................ ................................ ....... 26 
3.10 Visit Summary  ................................ ................................ ................................ ................................ .........  26 
3.10.1  Visit 1:  Screening/Baseline (days - 45 to - 1) ................................ ................................ .................  26 
3.10.2  Visit 2: Surgery: (day 0)  ................................ ................................ ................................ ..................  27 
3.10.3  Visit 3:  Day 10 Follow -Up (+/ - 6 days)  ................................ ................................ ..........................  29 
3.10.4  Visit 4:  Week 6 Follow -Up (+/ - 7 days)  ................................ ................................ ..........................  29 
3.10.5  Visit 5: Month 3 Follow -Up (+/ - 14 days)  ................................ ................................ .......................  30 
3.10.6  Visit 6: Month Follow -Up (+/ -14 days)  ................................ ................................ ...........................  30 
3.10.7  Visit 7: 12 Month Follow -Up (+/-1 month)  ................................ ................................ .....................  31 
3.10.8  Visit 8: Month 24 Follow -Up (+/ -2 months)  ................................ ................................ ....................  31 
3.10.9  Optional Follow -Up Visit, Unscheduled Visit Procedures  ................................ ..............................  32 
3.10.10  Post-operative Rehabilit ation Guideline  ................................ ................................ .....................  32 
3.11 Receiving, Storage, Dispensing and Return of Investigational Product  ................................ ..................  32 
3.11.1  Receipt and accountability  ................................ ................................ ................................ ...............  32 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 2 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.11.2  Storage  ................................ ................................ ................................ ................................ .............  33 
3.11.3  Dispensing of Investigational Device  ................................ ................................ ..............................  33 
3.11.4  Return or Destruction of Investigational Product  ................................ ................................ ...........  33 
4 STATISTICAL ANA LYSIS  ................................ ................................ .............................. 33 
4.1 Treatment Group s ................................ ................................ ................................ ................................ .... 33 
4.2 Description of Study Endpoints  ................................ ................................ ................................ ...............  34 
4.2.1  Primary Composite Endpoint  ................................ ................................ ................................ ..........  34 
4.2.2  Secondary Endpoints  ................................ ................................ ................................ .......................  35 
4.2.3  Safety Assessments  ................................ ................................ ................................ ...........................  36 
4.2.4  Radiographic Assessments  ................................ ................................ ................................ ...............  36 
4.3 Hypotheses  ................................ ................................ ................................ ................................ ...............  37 
4.4 Sample Size Determination and Rationale ................................ ................................ ...............................  37 
4.5 Randomization  ................................ ................................ ................................ ................................ .........  39 
4.6 Stratification and Site Blocking  ................................ ................................ ................................ ...............  39 
4.7 Blinding  ................................ ................................ ................................ ................................ ...................  39 
4.7.1  Study Blinding  ................................ ................................ ................................ ................................ .. 39 
4.7.2  Subject Blinding  ................................ ................................ ................................ ...............................  39 
4.8 Interim Anal ysis (IA)  ................................ ................................ ................................ ...............................  40 
4.8.1  Procedures for Interim Analysis  ................................ ................................ ................................ ...... 40 
4.8.2  Conditional Power Calculation  ................................ ................................ ................................ ....... 41 
4.8.3  Rules and  Method for Increasing Sample Size  ................................ ................................ .................  42 
4.9 Effectiveness Analyses  ................................ ................................ ................................ ............................  43 
4.10 General Statistical Considerations  ................................ ................................ ................................ ...........  43 
4.11 Analysis Populations  ................................ ................................ ................................ ...............................  43 
4.11.1  Intent -to-Treat Population  ................................ ................................ ................................ ...............  43 
4.11.2  Per Protocol Population  ................................ ................................ ................................ ..................  43 
4.11.3  Safety Population  ................................ ................................ ................................ .............................  44 
4.11.4  Covariates  ................................ ................................ ................................ ................................ ........  44 
4.11.5  Missi ng Data  ................................ ................................ ................................ ................................ .... 44 
4.11.6  Multiple C omparisons and Multiplicity  ................................ ................................ ...........................  44 
4.12 Statistical Methods  ................................ ................................ ................................ ................................ ... 45 
4.12.1  Subject Disposition  ................................ ................................ ................................ ..........................  46 
4.12.2  Demographic and Baseline Characteristics  ................................ ................................ ....................  46 
4.12.3  Protocol Deviations  ................................ ................................ ................................ .........................  46 
4.12.4  Prior and Concomitant Medications  ................................ ................................ ...............................  46 
4.12.5  Primary Endpoint Analysis  ................................ ................................ ................................ ..............  46 
4.12.6  Secondary Endpoint Analyses  ................................ ................................ ................................ ..........  47 
4.12.7  Other Outcome Analyses  ................................ ................................ ................................ .................  47 
4.12.8  MRI ................................ ................................ ................................ ................................ ..................  47 
4.12.9  Safety Analyses  ................................ ................................ ................................ ................................  48 
5 SAFETY AND ADVERS E EVENTS  ................................ ................................ ............... 49 
5.1 Definitions  ................................ ................................ ................................ ................................ ...............  49 
5.1.1  Adverse Event  ................................ ................................ ................................ ................................ .. 49 
5.1.1.1  Expected Adverse Events  ................................ ................................ ................................ .................  49 
5.1.2  Adverse Device Effect  ................................ ................................ ................................ ......................  49 
5.1.3  Serious Adverse Events  ................................ ................................ ................................ ....................  49 
5.1.4  Unanticipated Adverse Device Effect (United States) ................................ ................................ ...... 50 
5.1.5  Reportable Incident (Canada)  ................................ ................................ ................................ .........  50 
5.2 Recording of Adve rse Events and Incidents  ................................ ................................ ............................  50 
5.3 Reporting  ................................ ................................ ................................ ................................ .................  51 
5.3.1  Adverse Event Reporting Period  ................................ ................................ ................................ ...... 51 
5.3.2  Reporting Adverse Events  ................................ ................................ ................................ ................  51 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 3 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 5.3.3  Reporting S erious Adverse Events and Incidents  ................................ ................................ .............  53 
5.3.4  Informed Consent Violation Reporting  ................................ ................................ ............................  56 
5.3.5  Protocol Deviation Reporting  ................................ ................................ ................................ ..........  56 
5.3.6  Progress Reports  ................................ ................................ ................................ .............................  56 
5.3.7  Final Report  ................................ ................................ ................................ ................................ ..... 57 
5.4 Unblinding Procedures  ................................ ................................ ................................ ............................  57 
5.5 Data Safety Monitoring Board  ................................ ................................ ................................ .................  57 
5.6 Study Stopping ................................ ................................ ................................ ................................ .........  57 
5.7 Medical Mo nitoring  ................................ ................................ ................................ ................................ . 58 
5.8 Assessment o f Risks and Benefits  ................................ ................................ ................................ ...........  58 
5.8.1  Risks of Procedure  ................................ ................................ ................................ ...........................  58 
5.8.2  Risks of Study Device  ................................ ................................ ................................ .......................  59 
5.8.3  Benefits of Study D evice  ................................ ................................ ................................ ..................  59 
6 DATA HANDLING AND  RECORD KEEPING  ................................ ............................ 60 
6.1 Confidentiality  ................................ ................................ ................................ ................................ .........  60 
6.2 Source Documents  ................................ ................................ ................................ ................................ ... 61 
6.3 Case Report Forms  ................................ ................................ ................................ ................................ .. 61 
6.4 Data Management  ................................ ................................ ................................ ................................ .... 62 
6.5 Records Retention  ................................ ................................ ................................ ................................ .... 62 
7 STUDY MONITORING, AUDITING, AND INSPECTING  ................................ ......... 62 
7.1 Study Monitoring  ................................ ................................ ................................ ................................ ..... 62 
7.2 Auditing and Inspecting  ................................ ................................ ................................ ...........................  63 
8 ETHICAL CONSIDERATIONS  ................................ ................................ ...................... 63 
8.1 Protocol Amendments  ................................ ................................ ................................ .............................  64 
8.2 Informed Consent  ................................ ................................ ................................ ................................ .... 64 
9 INVESTIGATOR TRAINING  ................................ ................................ ......................... 65 
9.1 Investigator Training  ................................ ................................ ................................ ...............................  65 
9.2 Training of Study Staff  ................................ ................................ ................................ ............................  65 
10 PUBLICATION PLAN  ................................ ................................ ................................ ......66 
11 INSTITUTIONAL REVIEW BOARD / RESEARCH ETHICS BOARD  .................... 66 
12 REFERENCES  ................................ ................................ ................................ ................... 68 
13.0   APPENDICES  ................................ .................  ERROR! BOOKMARK NOT DEFINED.  
13.1 Appendix A: Sample Core Informed Consent Form ................................ . Error! Bookmark not defined.  
13.2 Appendix B: Recommended Surgical Tech nique/Instruction for Use  ...... Error! Bookmark not defined.  
13.3 Appendix C: Draft Shoulder Imaging (MRI) Assessment Guidance  ........  Error! Bookmark not defined.  
13.4 Appendix D: Sample Financial Disclosure  ................................ ...............  Error! Bookmark not defined.  
13.5 Appendix E: Dra ft Monitor Plan  ................................ ..............................  Error! Bookmark not defined.  
13.6 Appe ndix F: Draft Rehabilitation Guidelines  ................................ ...........  Error! Bookmark not defined.  
13.7 Appendix G: Draft Case Report Forms  ................................ ....................  Error! Bookmark not defined.  
13.8 Appendix H: Week 6 Draft Shoulder Imaging (M RI) Acquisition Guidance .........  Error! Bookmark not 
define d. 
 
 
 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 4 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
  
STUDY PROTOCOL SIGNATURE PAGE  
 
Confidentiality Statement:    
This Clinical Investigational Plan (CIP) contains privileged or confidential information, which is 
the property of the Sponsor. I nformation may not be disclosed to a third party without w ritten 
authorization from the Sponsor.  
 
Regulatory Statement:  
This study will be conducted according to the protocol, the US Code of Federal Regulations 21 
CFR Part 50, 54, 56, and 812, the ethical principles originating from the Declaration of Helsinki, 
and Good Clinical Practice (GCP) as defined in ICH E6, and the ICH Guidelines. All aspects of 
this study will be conducted in accordance with all national, state, and local laws of the pertinent 
regulatory authorities.  
 
Investigator’s Statement:  
I understa nd the protocol  “A prospective, single blinded, multi -cente r, randomized, controlled, 
pivotal  study to assess the safety and effectiveness of the InSpace™ device for treatment of full 
thickness Mass ive Rotator Cuff Tears .” 
I agree to conduct this study in accordance with the design and specific provisions of the 
protocol in this CIP , the Clinical Study Research A greement, and all applicable regulations,  and 
to inform all who assist me in the conduct of this study of their responsibilities and obligations.  
I agree to ensure the rights, safety, and well -being of the subjects involved in the study.  
I agree to await Institutional Review Board (IRB)/Research Ethics Board (REB) approval of the 
CIP and Info rmed Consent Form (ICF) before initiating the study, to ob tain informed consent 
prior to subject enrollment in the study, to collect and record data as required by this CIP and 
corresponding Case Report Forms (CRF), to prepare Annual, Final, and Adverse Ev ents (AE) 
Reports as required, and to maintain study docum entation for the period of time required.  
 
 I agree to maintain responsibility for all medical devices under investigation.  
 
Investigator’s Printed Name:  
                                        
 
Investigator’s Signature:  
 Date of Signature:  
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 5 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 STUDY SYNOPS IS 
 
Title  A prospective, single blinded, multi -center, randomized, controlled, 
pivotal study to assess the safety and effectiveness of the InSpace™ 
device for treatment of full thickness Massive Rot ator Cuff Tears  
Short Title  InSpace device  
Protocol Num ber CLD -OR-010 
Study Design  Prospective, single blinded, multi -center, randomized, controlled,  
pivotal  
Study Duration  48 months total (approximately 24 month enrollment + 24 month 
follow -up) 
Study Center(s)  Up to 20 clinical sites (US and Canada)  
Num ber of 
Subjects  184 subjects  
Objectives  Primary:  
• To evaluate the safety and effectiveness of the InSpace device as a 
primary surgical treatment for full thickness massive rotator cuff 
tears  
Secon dary:  
• Change in clinical outcomes compared to baseline  
Study Population  Male and female ≥ 40 years of age presenting with a full thickness 
massive rotator cuff tear (MRCT)  
Study Treatment  Group I: InSpace device  
Control 
Treatment  Group II: Partial Repair  
Randomization 
Scheme  Subjects will be assigned by a 1:1 schema  
Route of  
Administration  Arthroscopic surgical implantation of the InSpace device  
Endpoints:  Primary Composite Endpoint  
• WORC improvement of 275 points by Week 6 from pre -operative 
baseline and maintained at  Month 12  
• ASES  improvement of 6.4 points by Week 6 from pr e-operative 
baseline and maintained at  Month 12  
• No subsequent secondary surgical interventions (SSSI) in the index 
shoulder through Month 12 
• Absence of Serious Adverse Device Effects (SADEs), through 
Month 12  
 Secondary Endpoints:  
Clinical endpoints  
• Compos ite endpoint component -level success for WORC 
compared to baseline  
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 6 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Composite endpoint component -level success for ASES compared 
to baseline  
• Change in Western Ontario Rotator Cuff Index (WORC) 
questionnaire scores  from baseline  
• Change in American Shoulder and Elbow Surgeons (ASES) from 
baseline  
• Change in Constant Murley Shoulder Outcome Score from baseline  
• Change in EuroQOL five dimensions questionnaire (EQ -5D-5L) 
from baseline  
• Change in Visual Analogue Scale (VAS) scores from baseline  
• Change in  Range of Mo tion (ROM) from baseline  
• Composite endpoint success at Month 24  
Imaging endpoints will include reading of MRI scans conducted at  
• Week 6 post treatment to assess (Group I: InSpace device 
[includes only subjects enrolled under Protocol V3.0, May 
1, 2017] ): 
i. device location in the sub -acromial space  
• Month 12 post treatment to assess  (all randomized 
subjects) : 
i. the device residuals (Gr oup I – InSpace only )  
the shoulder joint and surrounding tissue condition     (Group I: 
InSpace device and Group II: Partial Repa ir)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 7 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 TABLE 1:   STUDY FLOWCHART AND FOLLOW -UP ASSESSMENTS  
Procedure  Screening/
Baseline  Surgery   Post-Treatment Follow -up Evaluation  
Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  
Days  
- 45 to -1 Day 0  Day 10 
±         
6 d Wk 6  
±          
7 d M 3 
±         
14 d M 6 
±             
14 d M 12  
± 
1 m M 24 
±          
2 m 
Informed Consent  X1        
Pregnancy Test  (if 
applicable)   X2       
Medical History  X        
Demographics  X        
Subject Eligibility  
Criteria Verificat ion  X X       
Subject 
Randomization   X3       
Subject Treatment   X5       
Magnetic Resonance 
Imaging  (MRI)  X4   X6    
X7  
Western Ontario 
Rotator Cuff  Index 
(WORC)  X  X X X X X X 
American Shoulder 
and Elbow Surgeons 
(ASES)  X  X X X X X X 
EuroQOL  five 
dimensions 
questionnaire  (EQ-5D-
5L) X  X X X X X X 
Constant -Murley 
Shoulder Outcome 
Score  X   X X X X X 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 8 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Visual Analogue Scale 
(VAS)  X  X X X X X X 
Adverse Events   X X X X X X X 
Concomitant 
Medications Review  X X X X X X X X 
 
1. Must occur prior to  any study -specific procedures.  
2. If applicable, a pregnancy test, urine or blood, will be performed no earlier than 2 days 
before the scheduled surgery.  
3. Interactive web randomization performed after intra -operative inclusion confirmed.  
4. Pre-operative MRI tak en within 9 months of enrollment .  
5. Subject will be blinded to treatment assignment until end of study.  
6. MRI to all study treatment arm subjects  (Group I: InSpace device [includes only subjects 
enrolled under Protocol V3.0, May 1, 2017 ])at Week 6 per Imagin g Acquisition guidance  
(provided in Appendix  H)  
7. MRI to all randomized subjects as per imaging Acquisition guidance (provided in 
Appendix C ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 9 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 1  BACKGROUND INFORMATION    
1.1 Introduction  
 
Rotator cuff tears (RCTs) are amongst the most common orthopaedic condition in adults.  The 
incidence of rotator cuff tears increases in frequency with age (Lehman, 1995) and is often 
associated with degeneration of the tendons (Matava, 2005).  Full thickness tears of the rotator 
cuff are among the most commo n sources of pain and dysfunction in the shoulder (Bunker, 
2002).  Approximately 18 million Americans self -reported shoulder pain in 2005.  By 2030, over 
20% of the US population will be over 65, with that the prevalence of rotator cuff disorders are 
expec ted to increase over the next two decades (AAOS, 20 13).   
RCTs are classified by the size of the tear (Matthews, 2006), the presence of tendon retraction, 
chronicity of the injury (Coleman, 2003; Liu, 2011) and the amount of muscle atrophy and 
degree of fa tty degeneration (Harryman, 1991; Goutallier, 2007; Encalada -Diaz, 2011).  Tears 
may range in severity from partial to massive.  
Massive tears, commonly defined as a tear is greater than 5 centimeters in diameter (Cofield, 
1985) are frequently associated w ith pain, weakness, and functional disability (Jost, 2006; 
Gartsman, 1997).  Furthermore, these massive tears have demonstrated unfavorable outcomes 
following conservative care, necessitating surgical intervention.  
Although technically challenging, complet e primary repair of the massive tear may be achieved 
through open or arthroscopic procedures (Mellado, 2005). When a patient has pain and weakness 
in the setting of a massive tear which may not be amenable to complete repair, there are a variety 
of potenti al treatment options (Elhassan, 2008).  These options may include conservative 
management (e.g., physical therapy) (Walch, 2005), simple decompression and debridement with 
or without biceps tenotomy (or tenodesis), subscapular nerve release, biologic augme ntation, 
tendon transfer, partial repair, and reconstruction with hemiarthroplasty or reverse shoulder 
arthroplasty (Encalada -Diaz, 2011; Moser, 2007; Aurora, 2007; Goldberg, 2008; Cuff, 2008; 
Berth, 2010). A thorough history and physical examination are i mportant to establish the 
diagnosis and determine the most appropriate treatment.  The treatment algorithm is largely 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 10 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 based on the patient’s level of function, age, comorbidities, size and quality of remaining rotator 
cuff (Tonino, 2009).  
Arthroscopic part ial repair, as advocated by Burkhart et al. (Burkhart, 1997) attempts to restore 
function and provide pain reduction.  This approach involves surgical repair utilizing anchors or 
suture placement and requires a protracted period of recovery in order to pro tect the repair.  
Biomechanical studies have supported such partial repair approaches (Hsu, 2011; Burkhart, 
1997).  
Nevertheless, repair of massive tears is often followed by re -tears, additional muscular 
degeneration, and diminished clinical results over time (Galatz, 2004). Given this, there remains 
a need to evaluate potential alternatives which may prove effective in the treatment of full 
thickness massive rotator cuff tears.  
The study device, the InSpace™ device, is an inflatable  biodegradable balloon that is deployed 
arthroscopically into the subacromial space, acting as a spacer, in patients with full thickness 
massive RCTs.  The temporary lowering of the humeral head during spacer inflation may 
additionally provide improved balance between the subsca pularis anteriorly and the infraspinatus 
posteriorly, permitting better deltoid activation and compensation. The use of the InSpace device 
may be a simple and less invasive alternative that has the potential to provide comparable safety 
and effectiveness p rofile to the current, well -established technique of arthroscopic partial repair.  
The purpose of this study is to evaluate the safety and effectiveness of the InSpace device as a 
primary surgical treatment for full thickness massive rotator cuff tears. Sec ondary aims include 
evaluating additional clinical outcomes  and imaging . 
1.2 Device  Name and Intended Use  
The InSpa ce device under investigation is a biodegradable balloon  spacer provided by Ortho -
Space Ltd.   The InSpace device  is indicated for the treatment o f patients with massive, full -
thickness torn rotator cuff tendons due to trauma or degradation with mild to moderate gleno -
humeral osteoarthritis . 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 11 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 
1.3 Investigational Device  
The InSpace  system  components are single -use, supplied sterile and ready for use upon removal 
from their package (Figure 1 ). 
  FIGURE 1: INSPACE SYSTEM COMPONENTS : SPACER (BALLOON ),      
                        DEPLOYER AND  HANDLE  
 
 
 
 
 
 
 
 
 
 
The InSpace system is comprised of the following components:  
• Biodegradable, Inflatable Space r (Balloon)  
• Deployer and Handle  
 
The Biodegradable, Inflatable Spacer [(Balloon)  – InSpace device ] is a single use, 
biodegradable, inflatable spacer (balloon) implant  made of Poly  (L-lactide -co-ε-caprolactone)  
(Figure 2) .  
 
 FIGURE 2: INFLATED INSPACE DEVICE  BEFORE AND AFTER SEALING  
 
 
 
 Deployer and 
Handle  Protecting Sheath 
Tube  
Biodegradable, Inflatable 
Spacer (Balloon)  Over mold (Stainless Steel) tube and stopper  
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 12 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 
 
The InSpace  device  is folded inside the outer protecting sheath of the D eployer  (Figure 1 ).  
Through an arthroscopic procedure , following standard debridement/ ASD of the  shoulder,  the 
Deployer is placed in-situ and the InSpace device  is positioned in the sub -acromial  space 
between th e humeral  head and the acromion.  The InSpace  device  is inflated  with a physiological 
solution (i.e. , saline)  and sealed with the p lug attached to the tip of the internal inflation tube .  In 
this position,  the InSpace  device  fills the space created by the removal of the bursa thus allowi ng 
smooth gliding without friction of the humeral  head again st the acromion  (Figure 3 ).              
The InSpace device  degrades within 12 months, a period that may conform  well to the 
rehabilitation timeframe following a rotator cuff arthroscopic procedure.  
FIGURE 3: ILLUSTRATION OF THE INSPACE DEVICE PLACED IN THE SUB -ACROMIAL SPACE  
 
 
 
 
 
  The InSpac e device  has three optional sizes and volume  specifications  (Table 2 ). 
TABLE 2: INSPACE  DEVICE SIZE AND ASSOCIATED VOLUMES  
Size AP 
(mm)  ML 
 (mm)  Thickness 
(mm)  Wall thickness 
(µm)  Maximal  
volume  to 
spread the 
spacer (cc)  Recommended 
final inflation 
volum e (cc)  
Small  50 40 6 95-300 13-15 9-11 
Medium  60 50 6 95-300 20-22 14-16 
Large  70 60 6 95-300 40 23-25 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 13 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 The InSpace  Deployer and Handle is a single use, deploying system on which the InSpace device  
is loaded .  The Deployer  is composed of the following components:  
(1) An e rgonomic handle assembly made of biocompatible polycarbonate, white in color with 
red and green color knob s.  The handle serves for the InSpace device  insertion and provides the  
sealing mechanism for the InSpace device , positioned  and inflated in-situ.  
(2) An e xternal stainless steel  overmold tube with plug, mounted on an internal stainless steel 
inflation needle . This component is intended for InSpace device  insertion, inflati on and sealing 
(Figure s 1 and 2 ). 
(3) A protecting sheath tube that provides the InSpace device  external protection  while  
performing the  arthroscopic placement of the InSpace device in the sub -acromial space . 
1.4 Regulatory Status  and Human Clinical Data  
The InSpace system was CE ( Conformité Européenne,  2011) marked in July 2010 and is 
available for distribution throughout Europe.  Since its approval , over two thousand  (2000) of  the 
InSpace  devices were  implanted into patients diagnosed with RCT .  
Within these implantation s the company received 19 (~1%) complaints of medical events  which 
included  events such as deterioration in shoulder pain, device dis placement , inflammatory 
reaction to the device, and suspected infection.   Although not necessarily related to the device, 
twelve (12)  of these events (0.75%  95% exact bi nomial CI; [0.39% - 1.17%])  required device 
explantation, and  nine (9) events (0.56%  95% exact binomial CI; [0.26% - 1.07%]) were 
associated with suspected infection. No events associated with deep joint infections were 
reported. All subjects that underwen t explantation of the device were fully recovered following 
the procedure with no further complications .
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 14 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Additional d ata has been collected in a single center study ex ecuted in Slovenia  that 
enrolled  24 subjects. Eligible subjects were diagnosed  with rotator cuff tears ( Senekovic  et 
al. 2013) . The subjects were divided to two groups – scheduled for repair or un -repairable. 
This study cited no serious adverse device effects (SADE) . Significant improvement s in 
subjective pain scores commencing at 1 week post -implantation and a decrease in reported 
night pain w ere observed . Two of the subjects were suspected to have synovitis based on  
Magnetic Resonance ( MR) Imaging.  This was considered non -clinically significant and no 
bone  formation were observed at the 3 -year time point.  
Further to this publication  the study was prolonged up to  5 years post -operative follow -up.  
Of 15 subjects who completed the 5 years assessment 86,6% (13/15) maintained an 
improvement of at least 15 points in the TCS  with no evidence of A dverse Device Effects. 
A change of over 10 points is  considered clinically  significant .  
An additional study  that was conducted in 5 clinical sites in Israel, 58 subjects diagnosed  
with rotator  cuff tear underwent InSpaceTM implantation and were followed f or one year 
post implantation.  
Throughout the study the subjects exhibited an improvement from a Total Constant S core 
of 36 at baseline to 64.3 at one year follow up.   
There were two Serious Adverse Device Effects  (SADEs) during the course of this study. 
One event resulted in the subject ’s hospitalization with antibiotic treatment due to the 
subject’s advanced age (8 1) and concomitant Diabetes and the other required device 
explanation.  Both events were resolved, one following conservative treatment and the  
other following an additional arthroscopic procedure.  
As the expected range for SADEs following the use of implants in orthopedic surgeries 
ranges from 4% to 19% (Freehill , 2003 ], the SADE rate presented in this study,  which is 
3.45% (95% exact confidence  interval: [0.42% -11.99%]) indicates an acceptable risk for 
the implantation and use of the InSpaceTM device.  
There were no unexpected adverse events in this study. All adverse events in the study 
were classified as either mild or moderate with no events classified as severe. Most of 
these events resolved within a few days of initiation, with either conservative treatment: 
medications (mainly analgesics) or observation only.   
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 15 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Adverse Device Effects (ADEs) following implantable orthopedic devices in the sho ulder 
are not uncommon and have been reported in up to 47% of the cases ( Böstman,  2000, 
Mulieri, 2010 ]. In this study, 15 out of the 58 subjects (25.8 6%) reported a total of 20 
ADEs  thus the ADE rate is 34.48% (95% exact confidence interval: [22.49% -48.12% ]). 
This rate was found to be clinically acceptable for a new implantable device, given the low 
rates of serious, device -related events.  
Following the  results of these two studies as well as the experience that was gained in the 
commercial use of over than  2000 implantations in Europe,  it can be concluded that the use 
of the Ortho -Space’s InSpace™ device in subjects with rotator cuff tears is a safe and 
effective treatment option associated with early improvement in the TCS and its related 
sub-scores.   
1.5 Mode  of Action  
The following section describes the mode of action of the InSpace  device  and is supported 
by in -vitro, animal , and human clinical studies . 
Following a standard diagnostic arthroscopy, the InSpace device  is positioned , using its 
deployment system , in the sub -acromial space between the humeral  head and the acromion . 
Once the deployer tube is placed in -situ the InSpace device  is exposed by pulling back the 
protecting sheath (which provides the InSpace device  external protection to allow 
arthroscopic  placement)  and exposing the folded InSpace device . Following removal of the 
protecting sheath the InSpace device  is inflated with a physiological solution  (i.e. saline)  
and sealed.  In this position, the InSpace  device  fills the space created by the remova l of the 
bursa thus allowing smooth gliding without friction of the humeral head against the 
acromion.  
The InSpace device  is designed to reduce pain  associated with the full thickness MRCT s.  
Because pain associated with  a full thickness MRCT may cause abn ormal motion, l imit 
function  and required  rehabilitation , quality of life may be greatly impacted.  Breaking the 
pain cycle is intended to allow patients the potential opportuni ty of temporary pain relief,  a 
return to more normal shoulder function,  and reduce the need for more invasive procedures  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 16 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 (i.e. reverse total shoulder arthroplasty) . This mode of action may lead to an enhanced 
quality of life.   
2 OVERVIEW OF INVESTIGATIONAL PLAN  
This is a non -inferiority , prospective, single blinded, multi -center, rando mized, controlled, 
pivotal study evaluating  the safety and effectiveness of the InSpace  device  as a primary 
surgical treatment for full thickness MRCT in  comparison to Partial Repair of a full 
thickness MRCT performed during an arthroscopic procedure.  The primary effectiveness 
endpoint is a composite endpoint consisting of four pre -specified components where each 
component must achieve success by Month 12.  In addition, a  complete Month 24  analysis 
will be submitted at  the conclusion of the study.  
2.1     Objec tives 
2.1.1 Primary  Objectives  
• To evaluate the safety and effectiveness of the InSpace device as a primary surgical 
treatment for full thickness massive rotator cuff tears  
2.1.2 Secondary  Objectives  
• Change in clinical outcomes compared to baseline  
2.2 Endpoints  
2.2.1 Primary  Composite  Endpoint  
• WORC improvement of 275 points by Week 6 from pre -operative baseline 
and maintained at  Month 12  
• ASES  improvement of 6.4 points by Week 6 from pre -operative baseline 
and maintained at  Month 12  
• No subsequent secondary surgical interventions  (SSSI) in the index 
shoulder through Month 12 
• Absence of Serious Adverse Device Effects (SADEs), through Month 12  
 
2.2.2 Secondary Endpoints  
• Clinical endpoints:  
o Composite endpoint component -level success for WORC  compared to baseline  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 17 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 o Composite endpoint componen t-level success for ASES compared to baseline  
o Change in Western Ontario Rotator Cuff Index (WORC) questionnaire scores from 
baseline  
o Change in American Shoulder and Elbow Surgeons (ASES) from baseline  
o Change in Constant -Murley Shoulder Outcome Score from baseline  
o Change in EuroQOL five dimensions questionnaire (EQ -5D-5L) from baseline  
o Change in Visual Analogue Scale (VAS) scores from baseline  
o Change in Range  of Motion (ROM) from baseline  
o Composite endpoint  success  at Month 24  
• Imaging endpoints will include  reading of MRI scans conducted at  
o Week 6 post treatment to assess  (Group I: InSpace device [includes only 
subjects enrolled under Protocol V3.0, May 1, 2017] ):  
▪ device location in the sub -acromial space  
o Month 12 post treatment  to assess  (all randomized su bjects) : 
▪ the device residuals ( Group I – InSpace only )  
▪ the shoulder joint and surrounding tissue condition (Group I: 
InSpace device and Group II: Partial Repair)   
 
2.2.3 Safety Assessment  
Safety will be evaluated by type, frequency, severity, and relatedness of  adverse events to 
study treatment and control treatment.  
3 PROTOCOL  
3.1 Study Design  
This is a  non-inferiority , prospective,  single blinded, multi -center, randomized, controlled, 
pivotal study . The study is designed to evaluate  the safety and effectiveness of t he InSpace  
device  as a primary surgical treatment for a full thickness MRCT in  comparison to Partial 
Repair of a full thickness MRCT performed during an arthroscopic procedure.  
 
The study will enroll 184 subjects presenting with a f ull thickness MRCT.  These 184 
subjects will be randomized 1 :1, producing approximately 92 subjects randomized to  the 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 18 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Study Treatment: Group I - InSpace  device  and 92 randomized to the Control Treatment: 
Group II – Partial Repair.  
Pharmacoeconomic data such as the subject’s bills  relating to the surgical procedure (i.e., 
operating room time, length of stay, medications, research center visits, rehabilitation and 
other related procedural costs) will be collected at the follow -up visits , if applicable .  In 
addition, procedural and d iagnostic codes, and reimbursement information may be 
collected.  Analysis of these data should allow a comparison of the net costs and net 
benefits of the study  treatment  to the control treatment .  These economic endpoints will not 
be included in the data  set for FDA submission because they do not relate to device safety 
or effectiveness.  
3.2 Subject Recruitment and Screening  
Subjects will be voluntarily recruited from the Principal Investigator or Sub -Investigator 
population and/or referring physicians.  
Subje cts who present with a full thickness MRCT  will be screened to determine if they 
meet all inclusion and no exclusion criteria. If all entry criteria are achieved, the subject 
will be eligible to participate in the study. All general and indication -specific  entry criteria 
must be met prior to study entry.  
All potential subjects screened for eligibility will be listed on the Screening and 
Enrollment Log. The Screening and Enrollment Log will document the date of screening, 
the results of screening, and the p rimary reason for excluding the subject (e.g., does not 
satisfy eligibility criteria or subject declined).  
Subjects who are eligible to enter the  study  will be provided with a n Institutional Review 
Board (IRB) or a Research Ethics Board (REB)  approved I nformed Consent Form (ICF)  
for review and signature. Each subject will have a physical exam of the index shoulder that 
incorporates a medical history and injury etiology.  Diagnosis of the rotator cuff tear will 
be confirmed with MRI acquired within 9 months of enrollment.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 19 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.3 Study Blinding  
The I nvestiga tor and surgical attendees will be unblinded  to the treatment assignment due 
to the nature of the surgical procedure  and post -op rehabilitation process .  
The subject will remain blinded  to the treatment assignment  until completion of the study.  
See section 5.4 for Unblinding Procedures.  
3.4 Study Duration and Follow -up 
The anticipated study duration is 48 months, which includes a n approximate  24 month 
enrollment period  and 24 month follow -up period .  
Subjects will be assessed pre -operatively and at Day 10, Week 6, and Month s 3, 6, 12, and 
24 post -operatively . At each follow -up visit,  a shoulde r examination will be performed,  
subject  questionnaires will be administered , and Adverse Events ( AEs) and concomitant 
medicatio n will  be reviewed, if applicable. All study treatment arm subjects  (Group I: 
InSpace device [includes only subjects enrolled under Protocol V3.0, May 1, 2017]) will 
receive an MRI at Week 6 to assess  device location.  
At Month 12 post-operatively , all randomized subjects will  complete a MRI  scan of the 
treated  shoulder .  
The Study Flowchart and Follow -Up Assessments table (Table 1) outlines study 
procedures and timelines . 
3.5 Randomization  
Centralized randomization will be performed,  and subjects will be random ly assigned to 
one of the following groups by a 1:1 schema:  
• Group I:  InSpace  device  
• Group II: Partial  Repair  
3.6 Selection of Subjects  
Subjects who meet all of the following criteria will be voluntarily recruited by participating 
Investigators:  
3.6.1 Inclusion Crit eria 
Subjects MUST meet ALL of the following criteria to be included in the study:  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 20 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 1. The subject h as signed the IRB/REB approved Informed Consent Form ( ICF) 
specific to this study prior to enrollment  
2. Is male or  female ≥ forty (40) years of age  
3. Positive diagnostic imaging by MRI within 9 months of enrollment of the index  
shoulder indicating a full thickness MRCT:  
a. measuring ≥  5 cm in diameter (Cofield classification)  
b. involving ≥ two tendons  
4. Functional deltoid musc le and preserved passive range of motion on physical 
examination  
5. Documented VAS score of  >30 mm pain  
6. Failed non -operative treatment of at least 4 months from the initial treatment to 
include one or all of the following:  
a. Oral analgesics  
b. Anti-inflammatory medication (e.g. , ibuprofen, naproxen)  
c. Corticosteroid injection(s)  
d. Physical therapy  
e. Activity modification  
f. Rest (sling used)  
7. Must be able to read and understand the approved Informed Consent F orm 
(written and oral)  
8. Must be in general good health (as determi ned by the Investigator) based on 
screening assessments and medical history  
9. Must be independent, ambulatory, and can comply with all post -operative 
evaluations and visits . 
 
3.6.1.1  Intra -operative Inclusion Criteria  
Subjects MUST meet the following criteria to be randomized in the study:  
• Full thickness tear  
• Tear size ≥5 cm in diameter (Cofield classification)  
• Tear involving ≥ two tendons  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 21 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.6.2 Exclusion  Criteria  
Subjects will be excluded from the study, if they meet ANY one (1) of the following 
criteria:  
 
1. Known allergy to the device  material (copolymer of PLA and  -ε-caprolactone)  
2. Evidence of the following conditions:  
a. severe gleno -humeral or acromiohumeral arthritis  
b. full thickness cartilage loss as seen on MRI  
c. history within the past 5 years of anterior or posterior shoulder subluxation or 
dislocation as determined  by history, examination or radiographic findings  
d. pre-existing deltoid defect or deltoid palsy  
e. major joint trauma, infection or necrosis  
f. partial thickness tears of the supraspinatous  
g. fully reparable rotator cuff tear [ Tear of less than 5  cm in diameter (or  < 4 cm2) 
with retractable te ndon that can be fully repaired]  
h. known neurovascular compromise  
i. complete deltoid muscle palsy  
j. traumatic muscle tears of the pectoralis or deltoid  
3. The subject requires concomitant:  
a. subscapularis repair  
b. labral repair  of any type  
4. Previous surgery of the index  shoulder in the past 1  year, excluding diagnostic 
arthroscopy  
5. The subject’s condition is bilateral and rotator cuff repair is scheduled or to be 
scheduled over the course of this study for the contra lateral shoulder  
6. Major med ical condition that could affect quality of life and influenc e the results of the 
study (e.g.  HIV or other immunosuppressive conditions, active malignancy in the past 
5 years, acute MI, CVA , etc.)   
7. The subject has documented evidence of a history (e.g. , liver testing) o f drug/alcohol 
abuse within12 months of  enrollment  
8. The subject’s condition represents a worker’s compensation case  
9. The subject is currently involved in a health -related litigation procedure  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 22 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 10. Females of child -bearing potential who  are pregnan t or breastfeeding or plan to become 
pregnant during the course of the study  
11. Concurrent participation in any other investigational clinical study  one month prior to 
enrollment or  during the entire study period  
12. The subject has implanted metallic devices ( e.g., cardiac pacemakers , insulin pumps,  
nerve stimulators), medically implanted clips or other electronically, magnetically or 
mechanically activated implants that wo uld contraindicate undergoing a  MRI scan of 
the index shoulder  
13. The subject has claustropho bia that would inhibit their ability to undergo a  MRI scan 
of the index shoulder  
14. The subject is physically or mentally compromised (e.g., currently being treated for a 
psychiatric disorder, senile dementia, Alzheimer’s disease,  etc.), to the extent that t he 
Investigator judges the subject to be unable or unlikely to remain compliant to follow -
up 
15. The subject is receiving prescription narcotic pain medication for conditions unrelated 
to the index shoulder condition  
16. The subject currently has an acute infectio n in the area surrounding the surgical site . 
17. Baseline WORC score less than 420.  
3.6.2.1  Intra -operative Exclusion Criteria  
Subjects will not be r andomized and will be terminated  from the study if they meet 
any one (1)  of the following intra -operative exclusion cri teria:  
• Rotator cuff is /presents with : 
o fully reparable with adequate tissue quality ( equivalent  to Goutallier 
stage 1 or 2)  
o partial thickness tear  of the supraspinatous  
o evidence of significant osteoarthritis  
• The subject r equires concomitant : 
o subscapularis repair  
o labral repair of any type  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 23 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Coracoacromial ligament functional deficiency is identified  
• Partial repair requires any type of grafting for enhancement of the partial repair 
procedure  
3.7 Early Withdrawal of Subjects  
3.7.1 When and How to Withdraw Subjects  
Subject s may voluntarily withdraw from the study at any time for any reason. The 
Investigator(s) may elect at any time to withdraw a subject from the study for any reason 
unrelated to the study if such a decision is in the subject’s best medical interest. Subject s 
who experience an AE may also voluntarily withdraw or be withdrawn if deemed in the 
subject’s best medical interest. Subjects with a secondary surgical intervention to the index 
shoulder will also  be discontinued in the study.  If a subject discontinues the study 
prematurely or is withdrawn by the Investigator(s), data collected up to the time of 
withdrawal will be used , if applicable , for analysis. The primary reason for termination or 
discontinuation will be documented on the End of Study  case report fo rm (CRF ). Subjects 
who are withdrawn  following randomization  for any reason from the study will  not be 
replaced.  
3.7.2 Data Collection and Follow -up for Withdrawn Subjects  
Subjects who withdraw consent and refuse to complete the follow -up assessment s, fail to 
adhere to protocol requirements, or die during the follow -up phase will be considered end 
of study at that time. Attempts will be made to retrieve any follow -up data, in particular, 
regarding possible AEs at the time of study discontinuation. If the Investig ator(s) reports a 
subject as lost to follow -up, the Clinical Research Associate (CRA) will ensure that the 
designated study staff has documented  the reason(s) this occurred and has ensure d that 
every attempt was made by the Investigator(s) to contact the s ubject to determine subject 
status. Appropriate documentation will consist of at least two documented attempts at 
contact via telephone, followed by an attempt to contact via a registered US/Canada post 
letter.  
3.7.3 Study Site Termination  
A specific study site in this multi -center study may also warrant termination under the 
following conditions:  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 24 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Failure of the Investigator to enroll  subjects i nto the study at an acceptable rate;  
• Failure of the Investigator to comply with Food and Drug Administration ( FDA ) 
and H ealth Canada  (HC) regulations,  the International Conference on 
Harmonization ( ICH) guidelines, IRB/R EB policies and procedures ; 
• Knowingly submitting false information from the study site  to the Sponsor or its 
designee, IRB/REB, and/or regulatory body(s), a s applicable; or  
• Insufficient adherence to protocol requirements.  
Study termination will be performed in compliance with the Sponsor ’s standard 
procedures.  
3.8 Prior and Concomitant Therapy  
Information on concomitant medications used will be recorded on the Co ncomitant 
Medication CRF.  Any ongoing medication used by the subject within 4 months  of 
enrollment will be considered concomitant medication (e.g. , aspirin, Tylenol, vitamins, 
dietary supplements, etc).  Any changes in medication must be noted on the Conc omitant 
Medication CRF.  
Any other investigational drug or approved therapy for investigational use is not permitted 
during study participation.   
3.9 Study Interventions  – Full Thickness MRCT  
A diagnostic arthroscopic evaluation will be conducted to confirm the diagnosis  of full 
thickness  MRCT . Once intra -operative eligibility is confirmed , the subject will be 
randomized to receive one of the following treatments:  
• Group I – InSpace  device  
• Group II – Partial Repair  
 
3.9.1 Clinical and Functi onal Assessments  
All subjects will be cli nically evaluated by the I nvestigator or a qua lified individual noted 
on the Delegation of A uthority (DOA) log.  Clinical and functional assessments will be 
measured as noted below:  
• Western Ontario Rotator Cuff I ndex (WORC): a subject  self–report questionnaire 
that is a disease -specific Quality of Life Measurement Tool specifically designed to 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 25 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 evaluate quality of life in  persons with pathology of the rotator cuff.  It is comprised 
of 21 items in 5 domains (i.e., physi cal symptoms, sports and recreation, work, 
lifestyle, emotions).  
• American Shoulder and Elbow Surgeons (ASES): a subject self -report 
questionnaire and Investigator assessment questionnaire.  The subject portion 
collects information on pain (i.e., 5 question s plus a VAS), instability (using a 
VAS) and activities of daily living (i.e., 10 questions) . The MCID for the ASES has 
been determined to be 6.4 points, which is the value that is associated with the 
patient’s perception of meaningful change (Michener LA,  2002) .  The Investigator 
assessment portion documents ROM, signs, strength, and instability.  
• Constant -Murley Shoulder Outcome Score: performed by the Investigator or 
designee to assess the shoulder and determine at minimum the ROM, external 
rotation and i nternal rotation, and power score.  
•  EuroQOL five dimensions questionnaire (EQ -5D-5L): a subject self-report 
questionnaire to measure health -related quality o f life (HRQOL). It consists of 5 
questions capturing  the subject’s current health across  five dime nsions  (i.e., 
mobility, self -care, usual activities, pain/discomfort and anxiety/ depressio n). It also 
includes  a numerical  visual analogue scale (EQ -VAS).  
• Visual Analogue Scale (VAS): a subject self -report questionnaire to measure pain . 
The patient marks o n the line the point that they feel represents their perception of 
their current state.   The amount of pain that a patient feels ranges across a 
continuum from none to an extreme amount of pain.  
 
3.9.2 Magnetic Resonance Imaging (MRI)  
At Week 6 post -operatively, a ll study treatment arm subjects  (Group I: InSpace device 
[includes only subjects enrolled under Protocol V3.0, May 1, 2017]) will receive an MRI 
to assess  device location.  
Week 6  post-operative MRI assessments will consist of rea ds completed by an un -blinded 
radiologist (s) 
• Group I: InSpace device  
o to assess  the device location in the sub -acromial space  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 26 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 At Month 12 post -operatively, all randomized subjects will complete a MRI scan of the 
treated shoulder.  
Month 12  post-operative MRI assessments will consist of reads completed by blinded  
radiologist (s).   
The following MRI scans reads  will be performed at Month 12 for the Study  
• Group I: InSpace device  
o to assess the device residuals at Month 12  post treatment  
o to assess the shoulder joint and surrounding tissue condition  at Month  12  
post treatment  
• Group II: Partial Repair  
o to assess the shoulder joint and surrounding tissue condition at Month  12 
post treatment     
3.9.3 Ultrasound  
The first fifteen (15) study treatment arm subjects received  an ultrasound to measure 
device position. Ultrasound was performed at Visit 3, 4 and 5 post implantation.  The 
ultrasound series is now complete.  
3.10 Visit Summary  
3.10.1  Visit 1:  Screening/Baseline  (days - 45 to - 1) 
All potential subjects screened f or eligibility will be listed on the Screening and 
Enrollment Log. The Screening and Enrollment Log will document the date of screening, 
the results of screening, and the primary reason for excluding the subject (e.g., does not 
satisfy eligibility criteria  or subject declined) . 
Qualified subjects who agree to participate in the study will be required to sign an  IRB/  
REB approved ICF.  After signing the IRB/ REB approved ICF , study subjects will 
undergo study -specific procedures  and the following activities will be performed.   
• Clinical Assessment:  
Data collected will include but not be limited to:  
• Confirm written informed consent, prior to any screening procedures  
• Eligibility criteria verification (inclusion/exclusion criteria)  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 27 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Medical and surgical history  
• Previous non-operative  treatment  
• Demographics (e.g., age, sex, date of birth, height, weight)  
• Work status, living environment, nicotine use  
• Concomitant medication, if applicable  
• Mechanism of injury, if applicable  
• Screening number assignment  
• Confirm Visi t 2 (surgery) scheduled within 45 days after screening  
• Evaluation Assessment:  
Data collected will include, but is not limited to:  
• Constant -Murley Shoulder Outcome Score  
• ASES   
Each subject will be asked  to complete the following subject self -report questionna ires 
following the shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
Pre-operative imaging includes  (within 9 months of enrollment ): 
• MRI  
3.10.2   Visit 2 : Surgery:  (day 0)  
If the Investigator(s) discovers the presence of a condition at the time of the procedure that 
woul d render the subject ineligible for study participation, the subject should be considered 
as an intra -operative failure and be discontinued from the study.  The subject should 
receive the standard of care as determined by the Investigator(s).   
The primary  reason for termination or discontinuation will be documented on the End of 
Study CRF . 
If the subject continues to meet eligibility criteria the information collected will include, 
but not be limited to:  
• Date of surgical procedure  
• Randomization assignment  
• Anesthesia type, time  
• Operating room times, procedure  times  
• Product related information  
• AEs 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 28 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Concomitant medications  
For females of child -bearing potential, a pregnancy test, urine or blood, will be performed 
no earlier than 2 days before the scheduled surg ical procedure, if applicable.  
3.10.2.1  Intra -operative  Procedure  
• Randomization  
• If the subject continues to meet all of the intra -operative inclusion and none 
of the intra -operative exclusion they will be randomized to receive  one of 
the following : 
▪ Group I: InSpac e Device  
▪ Group II: Partial Repair  
• Intra -operative Inclusion  Criteria  
Subjects MUST meet the following criteria to be randomized in the study:  
• Full thickness tear  
• Tear size ≥5 cm in diameter (Cofield classification)  
• Tear involving ≥ two tendons  
• End of Stud y – Intra -operative Exclusion  
Subjects will not be randomized and be considered end of study if they meet any one 
(1) of the following intra -operative exclusion criteria:  
• Rotator cuff is /presents with : 
o fully reparable with adequate tissue quality (equivale nt to Goutallier 
stage 1 or 2)  
o partial thickness tear of the supraspinatous  
o evidence of significant osteoarthritis  
• The subject r equires concomitant : 
o subscapularis repair  
o labral repair of any type  
• Coracoacromial ligament functional deficiency is identified  
• Partial repair requires any type of grafting for enhancement of the partial repair 
procedure  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 29 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 In case of intra -operative failure the subject will not be randomized into the study and will 
not be counted as a recruited subject (will be replaced with a new s ubject).  
3.10.3  Visit 3:  Day 10 Follow -Up (+/- 6 days)  
• Admission/Discharge information  
• Length of stay  
• Evaluation Assessment:  
Data collected will include, but is not limited to:  
• ASES - Shoulder examination  
• AEs, if applicable  
• Concomitant medication, if applica ble 
o Any changes in concomitant medication  
Each subject will be asked  to complete the following subject self -report questionnaires 
following the  shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
 
3.10.4  Visit 4:  Week 6 Follow -Up (+/ - 7 days)  
• Evaluation Assessment:  
Data collection and procedures will include but not be limited to:  
• Constant -Murley Shoulder Outcome Score  
• ASES - Shoulder examination  
• AEs, if applicable  
• Concomitant medication, if applicable  
o Any changes in concomitant medication  
• Compliance with Post -operativ e Rehabilitation Guideline  
Each subject will be asked to complete the following subject self -report quest ionnaires 
following the shoulder  exam ination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
Post-operative imaging includes:  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 30 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Week 6 MRI scan to all study treatment arm subjec ts (Group I: InSpace device 
[includes only subjects enrolled under Protocol V3.0, May 1, 2017])   
3.10.5  Visit 5: Month 3 Follow -Up (+/ - 14 days)  
• Evaluation Assessment:  
Data collection and procedures will include but not be limited to:  
• Constant -Murley Shoulder Out come Score  
• ASES - Shoulder examination  
• Assessment of evidence of infection (warmth, swelling, skin changes)  
• AEs, if applicable  
• Concomitant medication, if applicable  
o Any changes in concomitant medication  
Each subject will be asked to complete the following  subject self -report questionnai re 
following the shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
 
3.10.6   Visit 6: Month  Follow -Up (+/ -14 days)  
• Evaluation Assessment:  
Data collection and procedures will include but not be limited to:  
• Constant -Murley Shoulder Outcome  Score  
• ASES - Shoulder examination  
• Assessment of evidence of infection (warmth, swelling, skin changes)  
• AEs, if applicable  
• Concomitant medication, if applicable  
o Any changes in concomitant medication  
Each subject will be asked to complete the following sub ject self -report questionna ires 
following the shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 31 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.10.7  Visit 7 : 12 Month Follow -Up (+/ -1 month ) 
• Evaluation Assessment:  
Data collection and procedures will include but not be limited to:  
• Constant -Murley Shoulder Outcome Score  
• ASES - Shoulder examination  
• Assessment of evidence of infection (warmth, swelling, skin changes)  
• AEs, if applicable  
• Concomitant medication, if applicable  
o Any changes in concomitant medication  
Each subject will be asked to complete the following subj ect self -report questionna ires 
following the shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
Post-operative imaging includes:  
• Month 12 MRI  scan to all randomized subjects  (Both Arms)   
3.10.8  Visit 8 : Month 24 Follow -Up (+/ -2 months)  
• Evaluation Assessment:  
Data colle ction and procedures will include but not be limited to:  
• Constant -Murley Shoulder Outcome Score  
• ASES - Shoulder examination  
• Assessment of evidence of infection (warmth, swelling, skin changes)  
• AEs, if applicable  
• Concomitant medication, if applicable  
o Any c hanges in concomitant medication  
Each subject will be asked to complete the following subject self -report questionna ires 
following the shoulder examination : 
• WORC  
• EQ-5D-5L 
• ASES  
• VAS  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 32 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.10.9  Optional Follow -Up Visit, Unscheduled Visit Procedures  
Subjects that have pre-scheduled surgical visits not involving the index  or contralateral 
shoulder  (e.g., gallbladder removal, knee arthroscopy), and subjects that have additional 
visits beyond the study -scheduled visits and within the standard of care do not need 
documentat ion, unless associated with an AE (e.g., generalized AE or device/treatment -
related AE).  
3.10.10  Post-operative Rehabilitation Guideline  
Recommended guidelines for  post-operative rehabilitation are included  for consist ency in 
procedures across all study sites (App endix I) . 
3.11 Receiving, Storage, Dispensing and Return of Investigational Product  
3.11.1  Receipt and accountability  
The InSpace device will be shipped  directly to each study site  from Ortho -Space  Ltd., or 
designated affiliate.  
The Principal Investigator is responsib le for ensuring that accurate records are maintained 
for the receipt and dispensing of all investigational devices, including dates and number of 
investigational devices  received, to whom dispensed (subject -by-subject accounting), and 
accounts of any inves tigational devices  accidentally or deliberately dest royed .  Upon 
receipt of the shipment, inventory will be performed and an accountability log completed 
and signed by the person accepting the shipment.  The designated study staff will count 
and verify tha t the shipment contains all the items noted on the shipment inventory  list.   
Any damaged or unusable investigational device in a given shipment will be documented .  
The I nvestigator or designee must notify the S ponsor of any damaged or unusable 
investigat ional devices supplied to the investigator’s site. Peel -off labels on the InSpace  
device package are to be placed in the chart / source documents.  These records must be 
readily available for inspection by the Sponsor or designee ( if applicable) during rou tine 
site monitoring visits and are open to regulatory authorit y inspection at any time.  The 
Investigator may dispense investigational devices(s) only to subjects who have enrolled in 
the study and  have  signed the IRB/ REB approved ICF. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 33 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 3.11.2  Storage  
Until use, the InSpace device should be stored in a  secured,  clean , and dry area  with a 
maintained  temperature of 0-29°C (32-84.2°F) degrees.    
3.11.3  Dispensing of Investigational Device  
One (1) InSpace device  will be implanted  per subject according to the randomization 
assignment. It may be necessary to dispense three (3) InSpace devices to the operating 
room due to sizing availability. Reconciliation will be performed to document date used  or 
destroyed , subject assignment, and investigational device balance.  This reconci liation will 
be documented on the accountability log, signed and dated by the study staff.  Any 
discrepanc ies noted will be documented, investigated, and resolved .   
3.11.4  Return or Destruction of Investigational Product  
Unless otherwise specified, all unused investigational devices  must be saved for 
accountability purposes and returned to  the Sponsor or designated affiliate .  A copy of the 
accountability log must be forwarded to the Sponsor  or designated affiliate  with the 
returned or defaced investigational dev ices (as applicable).  
4 STATISTICAL ANALYSIS  
This section presents general information about statistical considerations and concepts 
such as randomization, stratification, statistical power, sample size, and a brief discussion 
on analysis methodology, as wel l as some data conventions. Detailed descriptions of the 
statistical analysis methods and data conventions will be in a separate document; i.e., the 
Statistical Analysis Plan (SAP) . 
4.1 Treatment Groups  
The following treatment groups will be assessed:  
Arm  Description  
Study Treatment  Group I: InSpace device  
Control  Treatment  Group II: Parti al Repair  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 34 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.2 Description of Study Endpoints  
4.2.1 Primary Composite Endpoint  
The primary  composite endpoint has four components as follows:  
• WORC improvement of 275 points by Week 6 from pre -operative baseline 
and maintained at  Month 12  
• ASES  improvement of 6.4 points by Week 6 from pre -operative baseline 
and maintained at  Month 12  
• No subsequent secondary surgical interventions (SSSI) in the index 
shoulder through Mont h 12 
• Absence of Serious Adverse Device Effects (SADEs), through Month 12  
 
The first component of the composite endpoint is a clinical measure.  WORC  is a validated 
and re liable disease -specific quality of life index that assesses multiple domains with 
twen ty-one (21) questions from five ( 5) domains that are scored with use of a 100 -mm 
VAS. The total score ranges from 0 to 2100, with higher scores indicating a worse 
outcome . Results from Kirkley et al. (2003) and Ekeberg et al. (2010)  have established a  
minimal important change of less or equal to 275 WORC points .  In this study , we use the 
mean difference for a component of the composite endpoint with success declared when a 
275-point improvement from pre -operative baseline is achieved by Week 6 and maintain ed 
at Month 12.   
The second component is an improvement in pain and function.  The American Shoulder 
and Elbow Surgeons Assessment Form (ASES) was developed as a standardized 
assessment of shoulder function  (Richards RR, 1994) .  The ASES patient self -reported 
section, consists of 2 dimensions: pain and activities of daily living (function).  The pain 
score is determined from a single pain question, and the function score from the sum of 10 
questions specific to activities of daily living. In this study, for a component of the 
composite endpoint we use the mean difference with success declared if a  6.4-point 
improvement  in the ASES computed score  from pre -operative baseline is achieved by 
Week 6 and maintained at  Month 12 .  This aligns with the ASES  MCID determined by  
Michener et al. (2002).     
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 35 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 The third component is the absence of any subsequent secondary surgical interventions 
(SSSI) in the index shoulder through Month 12. 
The fourth component is the Absence of Serious Adverse Device Effects (SADEs), 
throug h Month 12 . 
 
4.2.2 Secondary Endpoints  
Clinical Endpoints:  
• Composite endpoint component -level success for WORC  compared to baseline  
• Composite endpoint component -level success for ASES compared to baseline  
• Change in Western Ontario Rotator Cuff Ind ex (WORC) questionnaire scores from 
baseline . Mean and percent changes as well as the corresponding standard 
deviations will be calculated.  
• Change in American Shoulder and Elbow Surgeons (ASES) from baseline . Mean 
changes and standard deviations will be ca lculated.  
• Change in Constant -Murley Shoulder Outcome Score from baseline .  Mean 
changes and standard deviations will be calculated.  
• Change in EuroQOL five dimensions questionnaire (EQ -5D-5L) from baseline . 
Mean changes and standard deviations will be calcu lated.  
• Change in Visual Analogue Scale (VAS) scores from baseline . Mean changes and 
standard deviations will be calculated.  
• Change in Range of Motion (ROM) from baseline . Mean changes and standard 
deviations will be calculated.  
• Composite endpoint success at Month 24  
o Imaging endpoints will include reading of MRI scans conducted at : 
o Week 6 post treatment to assess  (Group I: InSpace device [includes only 
subjects enrolled under Protocol V3.0, May 1, 201 7]): 
▪ device location in the sub -acromial space  
o Month 12 post treatment  to assess  (all randomized subjects) : 
▪ the device residuals ( Group I – InSpace only )  
▪ the shoulder joint and surrounding tissue condition (Group I: 
InSpace device and Group II: Partial Repair)   
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 36 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.2.3 Safety Assessments  
Safety will be assessed by mon itoring the Adverse Events and tolerance post treatment , as 
detailed in SAFETY AND ADVERSE EVENTS  section of this protocol .  
Safety will be evaluated by type, frequency, severity, and relatedness of adverse events to 
study treatment and control treatment.  
 
4.2.4 Radiographic Assessments  
In the first year after surgery, the radiological assessment of the rotator cuff will serve as a 
supportive marker to establish the efficacy for the study success (based on the clinical 
evaluation of the index shoulder).  
Shoulder  MRI will be conducted per imaging acquisition guidance (Appendix C) in the 
following visits:  
• Visit 1 (Screening/Baseline): All Subjects (Both Arms): Pre -operative baseline 
MRI scan within 9 months of enrollment . 
• Visit 7 (12 Month Follow -Up): All Subjects (Both Arms):  
Group I: InSpace device  
• to assess the device residuals at 12 months post implantation  
• to assess the shoulder joint and surrounding tissue condition at 12 months post 
implantation.    
Group II: Partial Repair  
• to assess the shoulder joint and s urrounding tissue condition at 12 months post 
implantation.    
Additionally, at Week 6 all study treatment arm subjects  (Group I: InSpace device 
[includes only subjects enrolled under Protocol V3.0, May 1, 2017]) will receive an MRI 
to assess  the device lo cation in the sub -acromial space.  
Shoulder MRI will be conducted per imaging acquisition guidance (Appendix H) in the 
following visit:  
• Week 6 (Group I: InSpace device [subjects enrolled under Protocol V3.0, May 1, 
2017])  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 37 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 In addition, at any stage during th e follow up period, if deemed necessary by t he 
Investigator , (due to clinical symptoms such as suspected infection, suspected device 
displacement associated with deterioration in shoulder function  or symptomatic re-tear of 
the repaired rotator cuff) should er radiography (X -Ray) , ultrasound or MRI may be 
performed to confirm  shoulder condition or any surgery associated adverse effects . 
Imaging results will be assessed by independent certified radiologist.  
4.3 Hypotheses  
The null hypothesis is that there is at le ast a 10% disadvantage in the composite success 
percent for InSpace vs. Partial Repair Control  while the alternative hypothesis is that there 
is less than a 10% disadvantage for InSpace (PT) vs. Partial Repair Control  (PC). 
 H0:  P T – PC ≤ -10%  
versus 
 HA:  P T – PC > -10%.  
The non -inferiority design allows a penalty -free test for superiority in the event that non -
inferiority is established (one -sided p ≤0.025).  Non -inferiority will rule out the 10% non -
inferiority margin favoring InSpace while superiority will need to rule out a 0% margin 
favoring InSpace.  
This sequential hypothesis testing has the Type I error rates for both the non -inferiority and 
superiority controlled at one -sided 2.5% Type 1 error with superiority to be tested after 
non-inferiority as:    
H0: PT ≤ P C   
versus    
HA: PT > PC, 
4.4 Sample Size Determination and Rationale  
A total of 18 4 subjects (92 subjects per group) will be randomized to ensure that at least 
166 subjects (83  subjects per group) complete the study ; it is assumed that 10% will be 
exclud ed.  The hypothesis testing will be one -sided with 2.5% Type I error to test non -
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 38 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 inferiority with 80% power.  The null hypothesis of a 10% absolute disadvantage vs Partial 
Control will be tested against a 10% absolute advantage  vs. Partial Control for the purpose 
of sample size justification .   
Table 1.A.1 display s the sample size for various surgical control success percents 
ranging from 50% to 62.5%  for the composite endpoint; this will be adjusted at the 
interim analysis.  The 50% success percent is the worst case and will decrease as the 
success rate deviates from 50%; the sample size would increase to 180 from 166.          
 
Table 1.A.1: Lower 97.5% confidence limit to rule out 10% N -I margin for success % 
differences: 80% power  
 1 2 3 
  Partial Repair  success %, PC 0.500  0.600  0.625  
  InSpace success % expected, PT 0.600  0.700  0.725  
  Lower limit for PT – PC, LL -0.100  -0.100  -0.100  
  Power (%)  80 80 80 
  n per group  90 85 83 
 
Table 1.A.2 presents the corresponding InSpace success percents that wo uld achieve 
statistical significance to rule out a 10% disadvantage.  For 166  completers , a 3.8 -4.2% 
InSpace advantage is needed (Columns 1 -2).   
 
Table 1.A.2:  Lower 97.5% confidence limit to rule out 10% N -I margin for success % 
difference: One -sided p=0 .025 
 1 2 3    
  Partial Repair  success %, PC 0.500  0.600  0.625     
  InSpace success % expected, PT 0.538  0.641  0.6667     
  Lower limit for PT – PC, LL -0.100  -0.100  -0.100     
  n per group  90 85 83    
 
Table 1.A.3 presents the corresponding InSpace  success percents that would achieve 
superiority.  A 14 -14.2% InSpace  advantage is needed (Columns 1 -2).   
 
  Table 1.A.3:  Lower 97.5% confidence limit to establish superiority for success % 
difference: One -sided p=0.025  
 1 2 3    
  Partial Repair  success %, PC 0.500 0.600 0.625     
  InSpace  success % expected, PT 0.642  0.74 0.764     
  Lower limit for PT – PC, LL 0.000  0.000  0.000     
  n per group  90 85 83    
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 39 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
  
4.5 Randomization  
This is a non-inferiority prospective, single blinded, multi -center , randomized , pivotal study . 
The randomi zation will be central and use a  mixed block size with a 1:1 ratio of study 
treatment group to control treatment group.  
An individual independent of the study  execution team will develop the randomization 
schedule. Subjects who h ave met all  of the inclusion and none of the  exclusion criteria, who 
have provided written informed consent will be randomly assigned to the study treatment 
group  or the control treatment group based on this randomization schedule. The 
randomization assign ment will be made through an Interactive Web Randomization System 
(IWRS).   
4.6 Stratification  and Site Blocking  
Stratification is used to assure a within -stratum -balanced distribution of subjects between 
the two groups. Prior to randomization, subjects will b e stratified based on  gender  and site . 
4.7 Blinding  
4.7.1 Study Blinding  
The study will remain blinded until all subjects complete the Month 12 evaluation.  The 
Month 12 report will contain all effectiveness results including clinical, imaging, and 
safety data.  
 
4.7.2 Subject Blinding  
Subjects will be blinded to treatment assignment until the complet ion of the study.  All 
efforts will be made to keep the subject blinded  through Month 24 .  Should a subject 
undergo subsequent arthroscopy for recurrent or new  symptoms, withdraw from the study, 
or be terminated from the study, the blinded assignment will be revealed to the subject and 
the Investigator will provide care as standard and usual.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 40 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.8 Interim Analysis (IA)  
An Interim Analysis (IA) will be conducted when approximately 80 per-protocol  subjects 
(~40 per treatment group) have been randomized and completed the Month 12  post-treatment  
follow -up.  Only subjects completing the Month 12 post -treatment follow -up, including early 
withdrawals,  will be included in the  interim analysis.  
The procedures for this IA will be based on a standard operating procedure (SOP) that has a 
well-established firewall to protect the integrity of the study , and the Type I Error rate will be 
adjusted to maintain the Trial -wise Error rate . The IA will be performed by an unblinded  
statistician, who is not otherwise associated with the conduct of this study . The IA will be 
conducted under the auspices of an independent Data Safety Monitoring Board (DSMB).  
The objectives of this  initial  IA are to apply a promising zone methodology  to make the 
following decisions : 
• Re-assess s ample size to evaluate the sample size estimations, which will serve in the  
planning of the remaining study . An unblinded  statistician will conduct the power 
analyses.  
• Assess futility of continuing the study  based on the interim data.  
The study will not be stopped for superiority.  
 
4.8.1 Procedures for Interim Analysis  
• Cutoff dates for collection of CRFs, data cleaning, database lock and analysis is 
establi shed based on an estimated target date of the  80th treated subject per protocol 
completing the Month 12 post treatment follow up.    
• All data received by the cutoff date is entered, validated, queries generated and 
resolved or pending queries documented.   
• The database is locked for the IA.  
• The locked database is saved in a drive to which only the unblinded statistician 
responsible for the IA has access.  
Using this data, the unblinded statistician will prepare safety summaries and calculate the 
follow ing m etrics for the primary end point:  
1. Composite success percents (P t and P c) at Month 12.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 41 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 2. The dropout rate at the time of the IA . 
3. The Conditional Power (CP) Analysis of the study  at the time of the IA (Chen, 
2004). (The method for this calculation is provided i n the paragraph below).  
4. The revised sample size requirement based on this IA (The rule and method for 
sample size recalculation and p -value adjustment are provided below).  
4.8.2 Conditional Power Calculation  
The CP will be calculated according to the below formu la (Chen, 2004) using the Month 
12 success  percent s for the study treatment group to control treatment groups   
CP (f1,z1) = Φ { z 1 / 
    –   zα  / 
  } 
Where:  
• CP(f 1,z1)  is the conditional power at the IA  
• Φ{.} is the cumulative distribution function of a standard Normal distribution 
(μ=0, σ2 = 1)  
• f1 is the fraction of patients enrolled and used in t he IA before decision of 
increasing the sample size  
• zα is the upper α bound  for standard Normal distribution  
• z1 is the standardized Normal, since the primary endpoint is based on 
proportions the z -score will be obtained from the following formula:  
z1 = ((pt – pc - δ)/√(( pt(1-pt)/nt) + (pc(1-pc)/nc))  
Where:  
o pt = the Composite success percent at Month 12 for the subjects in the study 
treatment group     
o pc = the Composite success percent at Month 12 for the subjects in the control 
treatment group   
o pt(1-pt) = the standard deviation for the subjects in the study treatment 
group  
o pc(1-pc) = the standard deviation for the  subjects in the c ontrol  
treatment  group  
o nt = the number of subjects in the study treatment  group  used in the IA  
o nc = the number of subjects in the c ontrol  treatment  group used in the IA  
o t = the InSpace  group  
o c = the Control group  
The resulting CP will be used to determine whether the sample size needs to be 
increased or remain unchanged.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 42 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.8.3 Rules and Method for Increasing Sample Size  
Rules:   
• If the conditional power at the time of the interim analysis is < 10 % then  the study 
will be terminated for futility .  
• If the conditional power is >=  10% but <36% , then the sample  size will not be 
increased and the study  will continue based on the original samp le size.  
• If the conditional power is >= 36% and less than 80% , then the sample size will be 
adjusted to retain the original power of 80% or doubling the sample size, whichever 
is the smallest.  
• If the conditional power is >=  80%, then  the study will conti nue as is.   
The sample size may also be adjusted to reflect the Partial Repair control success percent.  
 
If the dropout rate is >10% for reasons other than safety or effectiveness, then the sample 
size will be increased accordingly to ensure that the PP a ccrual target is met.  
Regardless of the size of the CP, the study  sample size will not be reduced.  
 
Data Provided to DSMB :  
The DSMB  will receive a statistical report, the details on the content of the  report is 
described in the DSMB  charter.     
 Stopping Rule:     
The study  will not be stopped for  superi ority . 
Information Provided to Sponsor by Data Safety Management Board (DSMB) : 
The DSMB  will make recommendations to  the S ponsor on the futility and sample size 
adjustment and any safety concerns.  
Type I Err or Rate Adjustment:   
The overall Type I error rate will be one -sided 2.5%, which is equivalent to two -sided 5%. 
There will be no Type I error rate adjustment as there is no intention to stop the study for 
efficacy benefit. In addition, the sample size is p lanned to be increased when the interim 
conditional power is promi sing and this will protect the Type 1 error  (Mehta, Pocock – 
2000).  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 43 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.9 Effectiveness  Analyses  
The primary  effectiveness  analysis will be conducted after all recruited subjects have reached 
their primary endpoint at the Month 12 post treatment .  This analysis will  evaluate the 
primary endpoint at Month 12 , plus all available imaging and key safety data ; results will be 
presented according to unblinded treatment group . This initial report will be  used to submit 
the primary results of the study.  
All subjects will be followed out to Month 24  to extend all analyses  through Month 24  for the 
end of study analysis .   Upon study completion, t he analysis for the secondary endpoints will 
be conducted and reported  inclusive of all available imaging and safety data .  This subsequent 
report will be used to submit the final results of the study, including the Month 12 and Month 
24 post treatment assessments.  
4.10 General Statistical Considerations  
All collected s tudy data will be presented in subject data listings. Statistical analyses will 
be performed using SAS® version 9.3 or later. Descriptive statistics (n, mean, standard 
deviation, median, minimum and maximum) will be calculated by treatment group for 
contin uous variables. Frequencies and percentages will be presented by treatment group for 
categorical variables.  
4.11 Analysis Populations  
4.11.1  Intent -to-Treat Population  
The Intent -to-Treat population is defined as all randomized subjects who have had  at least 
one post treatment  efficacy assessment  analyzed as treated.   
The ITT analysis population will be used as the primary analysis population supportive of 
superiority and will also be used to generate all other effectiveness endpoints  in support of 
superiority and to confirm non -inferiority . 
4.11.2  Per Protocol Population  
The per -protocol analysis set (PP) includes all subjects in the ITT analysis set without any 
major protocol deviation s. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 44 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Given that this is a non -inferiority analysis, t he PP analysis popula tion will be used as the 
primary analysis population  supportive of non -inferiority and will also be used to generate 
all other effectiveness endpoints in support of non -inferiority and to confirm superiority.   
4.11.3  Safety Population  
The Safety population is def ined as all randomized subjects who underwent the study 
surgical procedure ( i.e., InSpace device  or Partial Repair ). This population will be used for 
the analysis of safety parameters.  
4.11.4  Covariates  
For efficacy analyses, gender will be used as a covariate in  the primary endpoint analysis 
models  while gender and the baseline covariate will be used as covariates in secondary 
effectiveness endpoint analyses . 
4.11.5  Missing Data  
For efficacy evaluation data points , SAS PROC MI  will be used to deal with  missing data; 
the method will be detailed in the Statistical Analysis Plan ( SAP) for the study.  
4.11.6  Multiple Comparisons and Mul tiplicity  
For the primary endpoint, n on-inferiority hypotheses will be tested at Month 12 for the 
primary endpoint first and then for two first-ranke d secondary endpoints (WORC and 
ASES).  Type I error will be controlled by requiring significant (one -sided p≤0.025) for 
non-inferiority testing to achieve an extended claim in the following pre -defined order 
using the non -inferiority margins specified in the SAP :   
• Mean WORC change from pre -operative baseline is non -inferior at Week 6 and 
maintained at Month 12 for the InSpace device.  
• Mean ASES change from pre -operative baseline is non -inferior at Week 6 and 
maintained at Month 12 for the InSpace device.  
Superiority will also be tested if non -inferiority is proven penalty -free per claim using one -
sided p <0.025 since the alternative hypothesis of superiority is a subset of the alternative 
hypothesis of non -inferiority.  Thus, each endpoint, for which non -inferiority is 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 45 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 sequentially established, will then be tested for superiority; the inability to reach 
superiority for a specific endpoint will not terminate the sequential testing plan.  
There are no further multiple comparisons involving time or endpoints to i mpact the 
overall Type I error.  
4.12 Statistical Methods  
A SAP  will be developed and approved before the interim analysis database is locked. The 
SAP will present the detailed statistical methodology to be used in analyzing the efficacy  
and safety data from th is study .  
All the eff ectiveness  endpoints will be analyzed  using both the ITT (primary for 
superiority and secondary  for non -inferiority ) and PP  (primary  for non -inferiority and 
secondary for superiority ) populations .  The PP population will be  primary to test non-
inferiority while the  ITT population will be primary to test superiority.  The ITT 
population analyses will not be performed if less than 5% of the ITT population  is 
excluded  or did not use the randomized treatment . The ITT analysis will be perf ormed 
using the randomized treatment assigned  while t he PP analyses will be performed using the 
actual t reatment  used.  All safety analysis will be conducted using the safety population  
according to the actual study treatment .  
All primary and secondary endpoint s will be tested  using one -sided 97.5% confidence 
interval s.  All primary and secondary analyses will be repeated for the ITT population.  
All data collected will be summarized according to the variable type:  
• Continuous data summaries  comparing treat ment groups  will include:  
o Number of observations, mean, standard deviation, median, and minimum and 
maximum values.   
o Unpaired t -tests for the mean changes from baseline for each secondary 
outcome at each nominal visit.  
o Generalized Estimating Equation (G EE) analysis (SAS PROC MIXED) 
analysis including the respective baseline covariate, age, gender, treatment, 
visit, and visit -treatment interaction .  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 46 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Categorical data summaries will include:  
o Frequency counts and percentages.  
4.12.1  Subject Disp osition  
The disposition of all subjects who sign an ICF will be provided. The numbers of subjects 
screened, randomized, completed, and discontinued during the study, as well as the reasons 
for all post -treatment  discontinuations will be summarized by trea tment group. Disposition 
and reason for study discontinuation will also be provided as a by -subject listing.   
4.12.2  Demographic and Baseline Characteristics  
Demographic and baseline characteristic data will be summarized descrip tively and/or 
presented as a by -subject listing for the Safety population  and Per Protocol populations . 
4.12.3  Protocol Deviations  
The deviations occurring during the clinical study will be summarized and/or presented as 
a by-subject listing.  
4.12.4  Prior and Concomitant Medications  
Concomitant medic ations will be summarized separately for the Safety and Per Protocol 
population s. All prior and concomitant medications recorded in the case report form will 
be coded to the drug substance level ( i.e., generic term)  using the most recent version of 
WHO Dru g. Descriptive summaries, by treatment group, will be prepared using the coded 
term. All prior , continuing,  and new medications recorded in the case report form will be 
listed.   
4.12.5  Primary Endpoint Analysis  
The primary analysis will be a logistic regression model for Month 12 success with age, 
gender, and treatment as the model covariates for the PP and ITT  population s using the 
composite endpoint.  The method of Firth (Firth, 2013)  will be used to compute unbiased 
percent estimates of the composite endpoint for each treatment group from the logistic 
regression model odds ratio estimate . 
The same approach will be used for the Month 24 analysis using the PP  and ITT  
population s.   
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 47 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 4.12.6  Secondary Endpoint  Analyses  
Endpoint -specific Generalized Estimating Equation (GEE ) models ( SAS PROC MIXED)  
will be used to further evaluate the  secondary endpoints for non -inferiority and superiority 
using the PP and ITT population s. The non-inferiority margins (δ) will be prospectively 
defined in the AP.  The method will be  provided in detail in the SAP for the study.  
Additionally, the c omposite endpoint at Months 12 and 24 except  requiring: (1) no 
subsequent secondary surgical interventions ( SSSI) in the index shoulder, and (2) no 
Serious Adverse Device Effects (SADEs) will be performed with multiple time point 
iterations determining when WORC and ASES clinical improvements threshold are 
achieved. Th e method will be  provided in detail  in the S tatistical Analysis Plan (SAP) for 
the study.  
4.12.7  Other Outcome Analyses  
The following descriptive analyses will further support publications comparing the 
InSpace device with Partial Repair control as per the original SAP. Unpaired t -tests and 
one-sided 97.5%  confidence intervals will be computed at Weeks 6 and 12 as well as at 
Months 6, 12, and 24 for the PP and ITT population s: 
• Change from baseline in the mean and mean percent WORC scores  
• Change from baseline in the mean and mean percent American Shoulder an d 
Elbow Surgeons (ASES)   
• Change from baseline in the mean and mean percent Constant -Murley Shoulder 
Outcome Score  
• Distribution c hange from baseline in the EuroQOL five dimensions questionnaire 
(EQ-5D-5L)  
• Change from baseline in the mean and mean percent Visual Analogue Scale (VAS) 
scores from baseline  
• Change from baseline in the mean and mean percent Range of Motion (ROM)  
• Composite endpoint success at Month 24  
 
4.12.8  MRI  
MRI findings will be summarized descriptively .  At Month 12 post -treatment, shoulder 
joint and surrounding tissue condition for both InSpace and Partial Repair  will be 
described  .  In addition, the device residual will be evaluated for the InSpace group  at 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 48 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Month 12.   At Week 6, the device location in the sub -acromial space will be described f or 
the InSpace group only  (Group I: InSpace device [includes only subjects enrolled under 
Protocol V3.0, May 1, 2017] ). 
4.12.9  Safety Analyses  
All safety assessments will be tabulated and no hypothesis testing will be conducted in this 
analysis.  For continuous v ariables data , will be summarized by treatment group using n, 
mean, standard deviation, median, minimum and maximum values. For categorical 
variables , data will be summarized by treatment group using frequency and percentage.     
The Safety population will  be used for all analyses of safety. All safety parameters will be 
presented descriptively and as data listings.   
 
4.12.9.1  Adverse Events / Adverse Device Effects  
Adverse Events will be coded using most recent version of MedDRA. Treatment  Emergent 
AE’s (TEAE) are defined as events with an onset on or after the subject  randomization . 
TEAEs will be summarized by treatment group, System Organ Class, and preferred term. 
The following TEAE summaries will be provided:  
▪ Overall TEAEs  
▪ TEAEs by seve rity grade  
▪ TEAEs by relationship to study device.  
Related AEs (ADEs) will also be presented .  In addition, separate summaries of SAEs  and 
SADEs will also be presented.  
The total number of subjects with at least one AE/ADE and the number of AEs/ADEs will 
be derived.  If more than one AE/ADE with the same preferred term occurs within a 
subject during the study period, they will be counted only once for that subject using the 
worst reported severity and causal relationship to the intervention. AEs/ADEs will al so be 
tabulated versus worst severity and worst relationship to the intervention.  
Symptoms recorded before administration of intervention will only be presented in listings.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 49 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 5 SAFETY AND ADVERSE EVENTS  
5.1 Definitions   
5.1.1 Adverse Event  
An AE can be any unfavorable  and unintended sign, symptom, or disease temporally 
associated with the use of a study device, whether or not considered related to the study 
device.  
5.1.1.1  Expected Adverse Events  
Expected Adverse Events include:  
• Post-operative fever  
• Hematoma  
• Localized pain  
• Increase in shoulder pain  
• Sensation decrease at incision site  
• Inflammation  
• Infection  
• Prolonged surgery time due to device breakage or malfunction  
 
5.1.2 Adverse Device Effect  
ADEs are AEs caused by or related to the device.  
5.1.3 Serious Adverse Events  
Events are classif ied as serious if they meet any of the following criteria (in accordance 
with the recommendations of ICH [Federal Register, October 7, 1997, Vol. 62, No. 194, pp 
52239 -45]):  
• Results in death,  
• Is life -threatening (NOTE:  the term “life -threatening” in the d efinition of 
“serious” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe),  
• Requires inpatient hospitalization or prolonga tion of existing 
hospitalization,  
• Results in persistent or significant disability/incapacity,  
• Is a congenital anomaly/birth defect  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 50 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Additionally, events are classified as serious if they meet any of the following criteria:  
• Requires intervention to prevent permanent impairment/damage, or  
• Important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered a serious adverse device effect 
when, based upon appropriate medical judgment, they may jeopardize the 
subject and may require medical or surgical intervention to prevent one of 
the outcomes listed above.  
5.1.4 Unanticipated Adverse Device Effect  (United States)  
An Unanticipated Adverse Device Effect is described as any serious adverse effect on 
health or safety  or any life -threatening problem or death caused by or associated with a 
device, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan or application (including a supplementa ry 
plan or application), or any other unanticipated serious problem associated with a device 
that relates to the rights, safety, or welfare of subjects (21 CFR 812.3(s)).  
5.1.5    Reportable Incident (Canada)  
According to the Canadian Medical Devices Regulations  (Sections 59 and 81), a reportable 
incident is any incident that:  
(a) is related to a failure of the device or a deterioration in its effectiveness, or any 
inadequacy in its labeling or in its the directions for use; and  
(b) has led to the death or a seri ous deterioration in the state of health of a patient, 
user or other person, or could do so were it to recur.  
5.2  Recording of Adverse Events  and Incidents  
At each contact with the subject, the Investigator  or designee  must seek information on 
AEs through que stioning. Information on all AEs should be recorded immediately in the 
source document and in the appropriate AE module of the CRF. All clearly related signs, 
symptoms, and abnormal diagnostic procedures results should be recorded in the source 
document, t hough should be grouped under one diagnosis.   
All AEs occurring during the study must be recorded in standard medical terminology. The 
clinical course of each event should be followed until resolution, stabilization, or until it 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 51 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 has been determined that t he study intervention or study participation is not the cause. All 
unresolved AEs should be followed by the Investigator until the events are resolved, the 
subject is lost to follow -up, through the end of the study, or until it has been determined 
that the  study intervention or participation is not the cause (whichever timing occurs first). 
Any Serious Adverse Event (SAE) that occurs until thirty (30) days after the study and is 
considered to be related to the study device or study participation should be r ecorded and 
reported immediately.  
5.3  Reporting  
5.3.1 Adverse Event Reporting Period  
The study period during which AEs must be reported is defined as from the initiation of 
any study treatment or randomization through the end of the study intervention follow -up.  
5.3.2 Reporting Adverse Events  
Any AE (clinical sign, symptom, or disease) temporally associated with the use of this 
study device, whether or not considered related to the study device, shall be documented 
on the AE CRF, except those physical assessment finding s that are considered to be 
clinically insignificant.  
All AEs meeting the above noted criteria reported by the subject or observed by the 
Investigator will be individually listed. The description of the event (confirmed diagnosis, 
if available), date of o nset, date of resolution, severity and relationship to study device, 
action taken, outcome, and seriousness will be reported.  
The Investigator will evaluate all AEs as follows:  
• CTCAE Grade (Intensity) Assessment  
The guidelines outlined in CTCAE v4.03 will  be used for assessing the intensity of the 
event. The general guidelines for assessing the AE grade appear below.  Full guidelines 
may be obtained at http://evs.nci.nih.gov/ftp1/CTCAE . 
 
Table 3: CTCAE v4.03 General Guidelines  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 52 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Grade  Description  
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; 
limiting age -appropriate instr umental activities of daily living 
(ADL)*.  
Grade 3  Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self care ADL†.  
Grade 4  Life-threatening consequenc es; urgent intervention indicated.  
Grade 5  Death related to AE.‡  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
†Self care ADL refer to bathing, dressing and undressing, feeding se lf, using the toilet, taking medications, and not 
bedridden.  
‡Unlike the AE outcome assessment (see Section 13.3.2), a subject may have more than one Grade 5 event.  
-Common Terminology Criteria for Adverse Events (CTCAE), v4.03: June 14, 2010  
 
 
• Causality Assessment  
AEs will be assigned a relationship (causality) to the study treatment  or surgical 
procedure .  The Investigator will be responsible for determining the relationship 
between an AE and the study treatment /surgical procedure .  The type of event, 
organ system affected, and timing of onset of the event will be factors in assessing 
the likelihood that an AE is r elated to the study treatment /surgical procedure . 
Relationship of AEs to study treatment will be classified as follows:  
o Not Related : Any reacti on that does not follow a reasonable temporal 
sequence from administration of the study device AND that is likely to have 
been produced by the subject’s clinical state or other modes of therapy 
administered to the subject.  
o Related : A reaction that follows a reasonable temporal sequence from 
administration of the study device  or control surgical procedure  AND that 
follows a known response pattern to the suspected device /surgical 
procedure . 
• Action Taken as a Result of the Event  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 53 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 The action taken in terms of tr eatment provided will be as either: none, medication 
administered, therapy administered, surgery, study treatment unblinded, or other (with a 
specification).  
• Outcome Assessment  
The outcome of the event will be assessed as either: resolved, resolved with se quelae, 
ongoing, lost to follow -up or death.  Only one AE per subject is allowed to have an 
outcome assessment as “death.”  If there are multiple causes of death for a given subject, 
only the primary cause of death will have an outcome of death.  
5.3.3 Reporting Serious Adverse Events and Incidents  
For any SAE  the Principal Investigator must notify the Sponsor’s Medical Monitor, within 
24 hours of becoming aware of the event and send the completed Serious Adverse 
Event/Unanticipated Adverse Device Effect (SAE/UADE ) Report to the Sponsor’s 
Medical Monitor within 48 hours. In addition, all IRB/REB reporting requirements will be 
followed.  
The Principal Investigator shall make an accurate and adequate report of any SAEs or 
Unanticipated Adverse Device Effects (UADE) . The Principal Investigator shall 
document any such report on the appropriate CRF and fax/email any initial or follow -up 
report to the Sponsor‘s Medical Monitor and to the IRB/REB (as applicable) that has 
reviewed and continues to review the study.  
• Pre-exist ing Condition:  
A pre -existing condition, other than the condition being treated, is one that is 
present at the start of the study. A pre -existing condition is recorded as an AE if 
the frequency, intensity, or the character of the condition worsens during t he 
study.  
• General Physical Assessment Findings:  
At screening, any clinically significant abnormality should be recorded as a 
preexisting condition. At the end of the study, any new clinically significant 
findings/abnormalities that meet the definition of a  SAE must be recorded and 
documented as a SAE.   
• Post-study Serious Adverse Event:  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 54 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 All unresolved SAEs should be followed by the Investigator until the events are 
resolved, the subject is lost to follow -up, through the end of the study, or until it 
has been  determined that the study intervention or participation is not the cause 
(whichever timing occurs first). At the last scheduled visit, the Investigator 
should instruct each subject to report any subsequent event(s) until thirty (30) 
days after study compl etion that the subject or the subject’s personal physician 
believes to be related to participation in the study. The Investigator should 
notify the Sponsor’s Medical Monitor of any death or SAE occurring at any 
time after a subject has discontinued or term inated study participation that is 
related to the study.   
• Hospitalization, Prolonged Hospitalization, or Surgery:  
Any medical conditions that occurs after randomization and results in 
hospitalization or prolonged hospitalization should be documented and r eported 
as a SAE unless specifically instructed otherwise in this protocol. Any 
condition responsible for surgery should be documented as a SAE if the 
condition meets the criteria for a SAE.   
Neither the condition, hospitalization, prolonged hospitalizatio n, nor surgery 
are reported as a SAE in the following circumstances:  
• Hospitalization or prolonged hospitalization for diagnostic or elective 
surgical procedures for a preexisting condition.  
• Hospitalization or prolonged hospitalization for therapy of the t arget 
disease of the study, unless it is a worsening or increase in frequency of 
hospital admissions as judged by the Investigator (e.g., secondary post -
operative hemorrhage).  
5.3.3.1  Investigator Reporting:  Notifying the Sponsor  
Any SAE or UADE must be reported to the Sponsor’s Medical Monitor via telephone, 
fax, or email within 24 hours of becoming aware of the event:  
 
SPONSOR’S MEDICAL MONITOR CONTACT INFORMATIO N 
Josh Krotec , MD  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 55 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Phone: 484 -832-8770  
Email: Global.SAEinbox@chiltern.com   
Within 48 hours after the  initial report, the Investigator must provide further information to 
the Sponsor’s Medical Monitor on the SAE or UADE in the form of a written narrative. 
This should include a copy of the completed SAE/UADE Report Form and any other 
related diagnostic inf ormation that will assist in the understanding of the event. Significant 
new information on ongoing SAEs should be provided promptly to the Sponsor’s Medical 
Monitor. All identifiable reference to the subject except for the subject screening number 
will be  redacted from any report sent to the Sponsor’s Medical Monitor.  
5.3.3.2  Investigator Reporting: Notifying Health Canada  
Investigators are responsible for reporting device related serious adverse events and 
incidents to Health Canada within 72 hours.  The Investi gator shall assist the S ponsor in 
generating a preliminary report within 10 days, containing preliminary observations, a 
course of action for the investigation, and a timeline for a final report (Section 60 of the 
Medical Device Regulations).  
5.3.3.3  Investigator Reporting: Notifying the IRB/REB  
Investigators are responsible for safety reporting to their IRB/REB. Investigators are 
responsible for complying with their IRB/REB’s reporting requirements for SAEs, though 
they must notify their IRB/REB within 10 working days of becoming aware of the event 
for any potential UADEs (21 CFR 812.150(a)(1)). The Investigator shall assist the Sponsor 
in generating the report of the UADE evaluation  within 10 days after the Sponsor first 
receives notice of the effect. (21 CFR 812. 46(b), 812.150(b)(1)).  
5.3.3.4  Reporting Deaths  
The following describes the Investigator reporting requirements in the event of a death, 
considered a SAE, which occurs during the course of a study:  
• Notify the Sponsor’s Medical Monitor within 24 hours of becoming 
aware of the event,  
• Provide the completed SAE/UADE Report Form to the Sponsor’s 
Medical Monitor within 48 hours of the event,  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 56 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Notify the IRB/REB of the death per IRB/REB reporting requirements.  
Should the Investigator determine the death to be device -relate d and unanticipated, it is 
considered an UADE, and the following Investigator reporting requirements should be 
followed:  
• Notify the Sponsor’s Medical Monitor within 24 hours of becoming 
aware of the event,  
• Provide the completed SAE/UADE Report Form to the Sponsor’s 
Medical Monitor within 48 hours of the event,  
• Notify the IRB/REB of the death per IRB/REB reporting requirements, 
but no later than 10 days of becoming aware of the event  
5.3.4 Informed Consent Violation Reporting  
If the Investigator uses the study dev ice without obtaining informed consent, the 
Investigator shall report such use to the Sponsor and the reviewing IRB/REB within 5 
working days after the use occurs (21 CFR 812.150(a)(5)).  
5.3.5 Protocol Deviation Reporting  
The Investigator shall notify the Spons or and the reviewing IRB/REB of any deviation 
from the protocol to protect the life or physical well -being of a subject in an emergency. 
Such notice shall be given as soon as possible, but in no event later than 5 working days 
after the emergency occurred (21 CFR 812.150(a)(4)).  All other deviations from the 
protocol will be reported on the appropriate CRF and reported to the IRB/REB, if required.  
Every effort shall be made to comply with the requirements of the protocol to avoid 
deviations.   
5.3.6 Progress Re ports  
The Investigator shall submit Progress Reports on the study to the Sponsor and the 
reviewing IRB/REB at regular intervals, but in no event less often than yearly (21 CFR 
812.150(a)(3)).  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 57 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 5.3.7 Final Report  
The Investigator shall, within 3 months after term ination or completion of the study or the 
Investigator's part of the study, submit a Final Report to the Sponsor and the reviewing 
IRB/REB (21 CFR 812.150(a)(6)).  
5.4 Unblinding Procedures  
Data are to remain blinded per protocol throughout the study. However, unblinding of 
subjects by the DSMB, data manager and/or statisticians  may occur  in the event of a SAE 
that is deemed related to the study intervention.  If time permits, the Investigator should 
make every attempt to c ontact the Sponsor and/or Medical Monit or before unblinding any 
subjects’ treatment. For emergent unblinding, appropriate study personnel must contact the 
Sponsor and the Medical Monitor as soon as possible after the incident to report the details 
surrounding the emergency unblind and to receiv e instruction on follow -up procedures.  
5.5 Data Safety Monitoring Board  
The Data and Safety Monitoring Board (DSMB) consists of a group of individuals  
(including independent Statistician  and at least one independent Senior  Orthopedic 
Surgeon  experience d with t he study indication ), appointed by the Sponsor or its designee, 
with pertinent expertise that will review accumulated data at the interim analysis from the 
study. The DSMB advises the Sponsor regarding the continuing safety of subjects and 
those yet to be voluntarily recruited to the study, as well as the continuing validity and 
scientific merit of the study. Unblinded data reviewed by the DSMB will be kept 
confidential and protected from inadvertent or inappropriate access by the Sponsor or its 
designee. F ollowing review of data generated from the interim analysis, the DSMB may 
advise the Sponsor to continue, redesign, or stop the study.  
5.6 Study Stopping  
The Sponsor may terminate the study at any study site, at any time, for any of the 
following reasons:  
• Non-compli ance to GCP  or protocol  
• Failure to enroll subjects  
• Major protocol deviations  
• Inaccurate or incomplete data  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 58 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Unsafe or unethical practices  
• Safety or performance considerations  
• Recommendation made by the DSMB  
• Administrative decision  
5.7 Medical Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study at 
his/her study site. Safety monitoring will include careful assessment and appropriate 
reporting of AEs. Medical monitoring will include a regular assessment of the  number and 
type of SAEs.  
5.8 Assessment of Risks and Benefits  
Any surgical procedure poses a potential risk, and the procedures undertaken as part of this 
study are no exception. There are always risks associated with any surgery or treatment 
and associated a nesthesia, including death.  
These risks have been minimized by establishing strict inclusion/exclusion criteria to 
assure only appropriate surgical candid ates participate in the study. A diagnostic 
arthroscopy will be used to confirm that al l inclusion cr iteria and no exclusion criteria are 
met.  In addition, only trained surgeons with expertise in sports medicine  and expertise in 
performing  arthroscopic shoulder procedures  will participate in this study.   
All study participants may benefit from having fr equent physician visits and close 
observation.  Additionally, th e results of this study  may benefit both physicians treating 
subjects and subjects  diagnosed with  full thickness MRCT s by generating data regarding 
the safety and outcome of the procedure.  
Subjects will be advised of the potential risks and benefits associated with this study in the 
IRB/REB  approved ICF.  
5.8.1 Risks of Procedure  
Possible risks that may occur post -operatively with  an arthroscopic treatment for a full 
thickness MRCT procedure are iden tified as  follows:  
• Deltoid detachment  
• Stiffness  
• Frozen shoulder  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 59 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 • Joint effusion  
• Tendon re -tear 
• Hematoma  
• Adhesions or arthrofibrosis  
• Hemarthrosis  
• Loss of motion  
• Localized pain  
• Sensation decrease at incision site  
• Inflammation  
• Wound i nfection  
• Wound drainage  
• Fever 
• Synovitis  
• Treatment failure due to rehabilitation non -compliance  
• Swelling and bruising  
• Nerve injury  
• Tendon Injury  
• Delayed wound healing  
• Vascular injury  
• Conversion to mini -open or open procedure  
• DVT  
• PE 
• General risks associated with surgery and anesthesi a (i.e., dizziness, 
fainting, difficulty breathing)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
5.8.2 Risks of Study Device  
Anticipated study device -related risks are identified belo w: 
• Tissue response to the implant  
• Re-operation of the index shoulder   
• Device displacement from the sub -acromial space  
• Prolonged surgery time due to device breakage or malfunction  
5.8.3 Benefits of Study Device  
Potential benefits of the study device include:  
• Redu ction of shoulder pain 
• Improved quality of life  
• Ability to return to activities of daily life  following short rehabilitation.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 60 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 6 DATA HANDLING AND RECORD KEEPING  
6.1 Confidentiality   
All information and data concerning subjects or their participation in this stud y will be 
considered confidential and handled in compliance with the ICH E6 and all applicable 
regulations  including the requirements of the Federal and Provincial Data Protection 
regulations, and additionally the Personal Information Protection and Electr onic 
Documents Act (PIPEDA 2000).  Those regulations require a signed subject authorization 
informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this 
study  
• Who will have access to that informat ion and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
Only authorized personnel, the Sponsor or its designee, and applicable regulatory bodies 
will have access to these c onfidential files. All data used in the analysis, reporting, and 
publication of this study will be maintained without identifiable reference to the subject.  
The HIPAA (Health Insurance Porta bility and Accountability Act) a uthorization adds to 
protections already provided by the elements of ICF and may be contained within the ICF 
document or as a separate document. The HIPAA document informs the subject that they 
can withdraw authorization to use data or samples not already submitted to the Sponsor or 
its designee and that the request must be in writing. If the subject allows samples to be 
used after withdrawal from the study, this permission may be withdrawn at a later date. 
The HIPAA authorization specifies who may review confidential medical information a nd 
to whom test results will be submitted. It also describes that test results obtained solely for 
research will not be part of a subject’s medical record.  
In the event that a subject revokes authorizat ion to collect or use PHI, the I nvestigator, by 
regula tion, retains the ability to use all information collected prior to the revocation of 
subject authorization.  For subjects that have revoked authorization to collect or use PHI, 
attempts should be made to obtain permission to collect at least vital status (i.e., that the 
subject is alive) at the end of their scheduled study period.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 61 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 6.2 Source Documents  
Source data is all information, original records of clinical findings, observations, or other 
activities in a study necessary for the reconstruction and evaluati on of the study. Source 
data are contained in source documents. Examples of source documents include, but are 
not limited to:  hospital records, clinical and office charts, laboratory notes, memoranda, 
subject’s diaries or evaluation checklists, pharmacy d ispensing records, recorded data from 
automated instruments, copies or transcriptions certified after verification as being accurate 
and complete, subject files, and records kept at the pharmacy, laboratories, and medico -
technical departments involved in t he study.  
The following data may be recorded directly in the CRF, which will then be considered as 
source data:  
• WORC  
• VAS  
• ASES  
• EQ-5D-5L 
• VAS  
• Imaging observations  
6.3 Case Report Forms  
The CRF is an integral part of the study and subsequent reports. The CRF prov ided by the 
Sponsor must be used to capture all study data recorded in the subject’s medical record. 
The CRF must be kept current to reflect subject status during the course of the study. Only 
a subject screening number will be used to identify the subject . The Investigator must keep 
a separate log of subject names and medical record numbers (or other personal identifiers). 
After obtaining written source document information from each subject at each visit, the 
study site will enter the data into the CRF (p aper or electronic). The monitor is responsible 
for performing on -site monitoring at regular intervals throughout the study to verify 
adherence to the protocol and applicable  regulations on the conduct of clinical research as 
well as to ensure completeness , accuracy, and consistency of the data entered in the CRF.  
At the study site, the monitor must have access to subject medical records, study -related 
records, and written source documentation needed to verify the entries on the CRFs. Final 
monitored and/o r audited CRFs will be available at all times, unless specified in writing to 
the Sponsor. These CRFs must be reviewed and verified for accuracy by the Principal 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 62 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Investigator and signed off (via electronic and/or paper signature). A copy of the final 
CRFs will remain at the Investigator’s study site at the completion of the study.  
6.4 Data Management  
Data management and handling will be conducted according to the study specific Data 
Management Plan in accordance with applicable guidelines.   
6.5 Records Retention  
Investigators are required to maintain all study documentation, including CRFs, ICFs, and 
adequate records for the receipt and disposition of the investigational device  according to 
the regulatory requirements and/or until notified by the Sponsor that the re cords may be 
destroyed. If the Principal Investigator retires, relocates, or for other reasons withdraws 
from the responsibility of keeping the study records, custody must be transferred to a 
person who will accept responsibility. The Sponsor must be notif ied in writing of the name 
and address of the new custodian.  
7 STUDY MONITORING, AUDITING, AND INSPECTING  
A monitor, whether an employee of the Sponsor or its designee, has the obligation to 
follow this study closely. In doing so, the monitor will visit the  study sites at periodic 
intervals, in addition to maintaining necessary contact. The monitor will maintain current 
personal knowledge of the study through obser vation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and  study  
staff.  Quality assurance auditors, whether an employee of the Sponsor or its designee, may 
evaluate study conduct at the study sites. These parties must have access to any and all 
study reports and source documentatio n, regardless of location and format. The Sponsor 
audit reports will be kept highly confidential.  
7.1 Study Monitoring  
Monitoring of study progress and conduct will be ongoing. The study will be monitored 
throughout its active phase. The first monitoring visi t during the active phase of the study 
will occur shortly after the first subject has been enrolled into the study at any particular 
study site. Subsequent monitor visits will occur as the frequency of enrollment dictates.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 63 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Monitoring of study activity will  be performed using several approaches (i.e., on -site, off -
site EDC).  The study data to be 100% monitored includes, but is not limited to the 
following: endpoints, SAE, randomization, consent, inclusion and exclusion criteria. The 
Investigator will alloca te adequate time for such monitoring activities. The Investigator 
will also ensure that the monitor or other compliance or quality assurance reviewer is given 
access to all the above noted study -related documents and study -related facilities (e.g., 
pharmac y, operating room, etc) and has adequate space to conduct the monitoring visit. All 
data recorded during the study will be available for audit against source data and for 
compliance with GCP (21 CFR Parts 11, 50, 54, 56, 812, ICH E6) and specific protocol 
requirements. The Principal Investigator will be responsible for the following:  
• Monitoring study conduct to ensure that the rights and well -being of subjects 
are protected;  
• Monitoring accuracy, completion, and verification of source documents; and  
• Monitori ng study conduct to ensure study compliance with the 
protocol/amendment(s), GCP, and applicable regulatory requirements.  
7.2 Auditing and Inspecting  
The Investigator will permit study -related monitoring, audits, and inspections by the 
IRB/REB, the Sponsor, go vernment regulatory bodies, and institution compliance and 
quality assurance groups of all study -related documents (e.g., source documents, 
regulatory documents, data collection instruments, study data, etc .). The Investigator will 
ensure the capability fo r inspections of applicable study -related facilities (e.g., pharmacy, 
operating room, etc .). 
Participation as an Investigator in this study implies acceptance of potential inspection by 
government regulatory authorities and applicable institution complianc e and quality 
assurance offices.  
8 ETHICAL CONSIDERATIONS  
This study will be conducted according to the protocol, the US Code of Federal 
Regulations 21 CFR Part 50, 54, 56, and 812, the ethical principles originating from the 
Declaration of Helsinki , and Goo d Clinical Practice ( GCP ) as defined in ICH E6, and the 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 64 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 ICH Guidelines. All aspects of this study will be conducted in accordance with all national, 
state, and local laws of the pertinent regulatory authorities.  
The decision of the IRB/REB concerning the conduct of the study will be made in writing 
to the Investigator and a copy of this decision will be provided to the Sponsor before 
commencement of this study. The Investigator should provide a list of IRB/REB members 
or an IRB/REB assurance number to the Sponsor.  
8.1 Protocol Amendments  
All protocol amendments must be submitted to the regulatory authorities  and the 
IRB/REB , as required.  A protocol amendment is generated by the Sponsor. The 
Investigator(s) is notified of the changes. The amended and/or revised  protocol cannot be 
implemented until IRB/REB and/or regulatory authority approval is received, as required. 
Protocol revisions that impact on subject safety, the scope of the study, or affect the 
scientific quality of the study must be approved by the reg ulatory authorities  and submitted 
to the IRB/REB  for approval before implementation of such revisions to the conduct of the 
study.    
The Sponsor may, at any time, amend this protocol to eliminate an apparent immediate 
hazard to a subject.  In this case, the  appropriate regulatory authorities will be subsequently 
notified.   In the event of a protocol revision, the ICF may require revisions, which must 
also be approved by the IRB/REB.  
8.2 Informed Consent  
All subjects for this study will be provided an IRB/REB app roved ICF describing this 
study and providing sufficient information for subjects to make an informed decision about 
participation in this study. This consent form will be submitted with the Clinical 
Investigational Plan (CIP) for review and approval by th e regulatory authority. The 
approved ICF will be submitted to the IRB/REB for the study. The formal consent of a 
subject, using the IRB/REB approved ICF, must be obtained prior to any study 
participation. The consent form must be signed by the subject and the Investigator and/or 
designated study staff obtaining the consent. A copy of the signed and dated ICF must be 
given to the subject, and the consent process must be documented in the source 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 65 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 documentation. Before recruitment and enrollment, each prospecti ve subject will be given 
a full explanation of the study, allowed to read the approved ICF, and be provided with 
ample time and the opportunity to ask any questions that may arise. Once all questions 
have been answered and the Investigator is assured that the subject understands the 
implications of participating in the study, the subject will be asked to give consent to 
participate in the study by signing the ICF. As part of the consent process, each subject 
must consent to direct access to his/her medical records for study -related monitoring, 
auditing, IRB/REB review, and regulatory inspection. If an amendment to the protocol 
changes the subject participant schedule or activity or increases the potential risk to the 
subject, the ICF must be revised and subm itted to the IRB/REB and regulatory authority 
for review and approval. The revised ICF must be used to obtain consent from a subject 
currently enrolled in the study if he/she is affected by the amendment, as deemed necessary 
by the reviewing IRB/REB. The r evised ICF must be used to obtain consent from any new 
subjects who are enrolled into the study after the date of the IRB/REB approval.  
9 INVESTIGATOR TRAINING  
9.1 Investigator Training  
The Sponsor will select only Investigator(s) with extensive experience in pe rforming 
arthroscopic shoulder  procedures. Training on the protocol will be provided prior to the 
start of the study. The protocol and instructions on how to complete the study 
documentation will be reviewed with the Investigator(s) and their study personn el at the 
Site Initiation Visit. All Investigators will be required to attend the initial investigator 
meeting  that will include training  on an inanimate shoulder model . Additionally, a field 
clinical trainer (Sponsor employee or designee) wi ll attend at m inimum the initial surgical  
procedure (s), as deemed necessary,  under the supervision of the Investigator.  
9.2 Training of Study  Staff  
The Investigator will ensure that appropriate training relevant to the study is given to the 
medical, nursing and other staff involved and that new information of relevance to the 
performance of this study is forwarded to the staff involved.  
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 66 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 10 PUBLICATION PLAN  
Authorship and contents of the publication shall be discussed between each Principal 
Investigator at the study site  partici pating in this study and the Sponsor.  The Sponsor shall 
serve as the coordinator of multi -center study disclosures and, in the eve nt of a 
disagreement among the I nvestigators, the Sponsor shall determine, in its sole discretion, 
the resolution of any such  dispute.  The Sponsor shall be furnished copies of any proposed 
multi -center publication or disclosure, including, without limitation, disclosures in papers 
or abstracts or at research seminars, lectures, professional meetings, or poster sessions, at 
least 90 days prior to the proposed date for submission for publication or disclosure.  
During such 90 -day period, the Sponsor shall have the right to review and require 
modification of such publication to assure the accuracy of the contents thereof and to 
delete Sponsor Confidential Information therefrom.  In addition, upon the Sponsor’s 
written request during the foregoing 90 -day period, the proposed submission for 
publication or disclosure shall be delayed for a period not to exceed ninety (90) days from 
the date of such request to permit the Sponsor to file patent applications or to otherwise 
seek intellectual property protection related to information contained in such publication or 
disclosure.   
It is also agreed that no presentations or publications will  be authorized individually or by 
subgroups participating in the s tudy without the consent of the Sponsor prior to publication 
of the pooled data; provided , however , that in no event shall any Institution or  Investigator 
involved in this s tudy be restricte d from submitting a publication independently after the 
expiration of 365 days from the completion of the multi -center study.  
11 INSTITUTIONAL REVIEW BOARD / RESEARCH ETHICS BOARD  
Before initiation of the study, the Investigator must obtain approval of the pr otocol, ICF, 
CRFs, and any advertisement for subject recruitment from an IRB/REB complying with 
the provisions specified in 21 CFR Part 56 or ICH GCP, as applicable, and pertinent 
government regulations.   
A copy of written IRB/REB approvals of the protoco l, ICF, CRFs, and any advertising for 
subject recruitment (if applicable) must be provided to the Sponsor or its designee prior to 
initiation of the study. The approval letter must be signed by the IRB/REB chairman or 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 67 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 designee, identify the IRB/REB name an d address, identify the protocol by title and/or 
protocol number, and include the date that approval was granted. The letter must also 
contain a statement that the IRB/REB complies with the requirements in 21 CFR Part 56 
for a study conducted under ICH or GCP, as applicable.  
The Investigator is responsible for obtaining continued review of the clinical research or 
submitting periodic progress reports, in accordance with applicable regulations, at intervals 
not exceeding one year or otherwise specified by th e IRB/REB.  
 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 68 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
  
12 REFERENCES   
 
Acute Pain Management:  Operative or Medical Procedures and Trauma, Clinical Practice 
Guideline No. 1. AHCPR Publication No. 92 -0032; February 1992. Agency for 
Healthcare Research & Quality, Rockville, MD; pages 116 -117. 
American  Academy of Orthopaedic Surgeons. Appropriate use criteria for optimizing the 
management of full -thickness rotator cuff tears, September 20, 2013.  
Aurora A, McCarron J, Ianotti J, Derwin K. Commercially available extracellular matrix 
materials for rotator cuff repairs: state of the art and future trends. J Shoulder Elbow 
Surg. 2007;16(5 Suppl):S171 -S178.  
Berth A, Neumann W, Aviszus F, Pap G. Massive rotator cuff tears: functional outcome after 
debridement or arthroscopic partial repair. J Orthopaedic Trauma tol. 2010;11:13 -20. 
Burkhart SS . Partial repair of massive rotator cuff tears: the evolution of a concept. Orthop 
Clin North Am. 1997 Jan;28(1) :125-32. 
Boileau P, Brassart N, Watkinson DJ, Carles M, Hatzidakis AM, Krishnan SG. Arthroscopic 
repair of full -thickness tears of the supraspinatus: does the tendon really heal? J Bone 
Joint Surg Am. 2005;87(6):1229 -1240.  
Böstman  O,   Pihlajamäki H. Adver se Tissue Reactions to Bioabsorbable Fixation Devices. 
Clinical Orthopaedics & Related Research. 2000 (Volume 371); 216 -227 
Bunker T. Rotator Cuff Disease. Curr Orthop. 2002;16:223 -33.   
Cofield RH. Rotator cuff disease of the shoulder. J Bone Joint Surg A m. 1985;67: 974 -9. 
Cole BJ, ElAttrache NS, Anbari A. Arthroscopic rotator cuff repairs: an anatomic and 
biomechanical rationale for different suture -anchor repair configurations. Arthroscopy 
2007;23(6):662 -669. 
Coleman SH, Fealy S, Ehteshami JR, MacGillivr ayJD, Altchek DW, Warren RF et al. Chronic 
rotator cuff injury and repair model in sheep. J Bone Joint Surg Am. 2003;85:2391 -
2402  
Constant CR, Murley AH. A clinical method of functional assessment of the shoulder.Clin 
Orthop Relat Res. 1987 Jan;(214):160 -4. 
Cuff D, Pupello D, Virani N, Levy J, Frankle M. Reverse shoulder arthroplasty for the 
treatment of rotator cuff deficiency. J Bone Joint Surg Am. 2008;90:1244 -51 
Crim J , Burks R , Manaster BJ , Hanrahan C , Hung M , Greis P . 
Temporal  evolution  of MRI  findings  after arthroscopic  rotator  cuff repair. AJR Am J 
Roentgenology.  2010 Dec;195(6):1361 -6. 
de Witte PB, Henseler JF, Nagals J, Vliet Vlieland TP, Nelissan RG. The Wester n Ontario 
rotator cuff index in rotator cuff disease patients: a comprehensive reliability and 
responsiveness validation study. Am J Sports Med. 2012; 40(7):1611 -9. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 69 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Ekeberg OM, Bautz -Holter E, Keller A, Tveitå EK, Juel NG, Brox JI. A questionnaire found 
disease -specific WORC index is not more responsive than SPADI and OSS in rotator 
cuff disease. Journal of Clinical Epidemiology 2010; 63(5):575 -84. 
Elhassan B , Endres NK , Higgin s LD , Warner JJ . Massive irreparable tendon tears of the 
rotator cuff: salvage options. Instr Course Lect. 2008;57:153 -66Encalada -Diaz I, Cole 
BJ, MacGillivray JD, Ruiz -Suarez M, Kercher JS, Friel NA, Valero -Gonzalez F. 
Rotator cuff repair augmentation using a novel polycarbonate polyurethane patch: 
preliminary results at 12 months follow -up. J Shoulder Elbow Surg. 2011;20:788 -94. 
Firth David . Bias reduction of maximum likelihood estimates. Biometrika , 2013;  80:27–38. 
Freehill MQ, Harms DJ, Huber SM, Atlihan D, Buss DD. Poly -L-lactic acid tack synovitis 
after arthroscopic stabilization of the shoulder.  Am J Sports Med. 2003; 31(5):643 -7 
Galatz L, Griggs S, Cameron BD, Iannotti JP. Prospective longitudinal analysis of 
postoperative shoulder function: a ten -year follow -up study of full -thickness rotator 
cuff tears. J Bone Joint Surg Am. 2001;83 -A(7):1052 -1056.  
Galatz L, Ball CM, Teefey SA, Middleton WD, Yamaguchi K. The outcome and repair 
integrity of completely arthroscopically repaired large and massive rotator cuff tears. J 
Bone Joint Surg Am. 2004;86(2):219 -224. 
Gartsman GM. Massive, irreparable tears of the rotator cuff. Results of operative debr idement 
and subacromial decompression. J Bone Joint Surg Am. 1997;79(5): 715 -21. 
Gazielly D, Gleyze P, Montagnon C. Functional and anatomical results after rotator cuff 
repair. Clin Orthop Relat Res. 1994;304:43 -53. 
Gerber C, Fuchs B, Hodler J. The results  of repair of massive tears of the rotator cuff. J Bone 
Joint Surg Am. 2000;82(4):505 -15. 
Goldberg SS, Bell JE, Kim HJ, Bak SF, Levine WM, Bigilani LY. Hemiarthroplasty for the 
rotator cuff -deficient shoulder. J Bone Joint Surg Am. 2008; 90:554 -9. 
Goutalli er D, Postel JM, Bemageau J et al. Fatty muscle degeneration in cuff ruptures. Pre - 
and postoperative evaluation by CT scan. Clin Orthop Rel Res. 1994 Jul;(304):78 -83.  
Gummesson C, Atroshi I, Ekdahl C. The disabilities of the arm, shoulder and hand (DASH)  
outcome questionnaire: longitudinal construct validity and measuring self -rated health 
change after surgery. BMC Musculoskeletal Disorders 2003; 4:11.  
Harryman DT 2nd, Mack LA, Wang KY, Jackins SE, Richardson ML, Matsen FA 3rd. Repairs 
of the rotator cuff : correlation of functional results with integrity of the cuff." J Bone 
Joint Surg Am 1991; 73(7):982 -9. 
Hsu JE , Reuther KE, Sarver JJ, Lee CS, Tho mas SJ, Glaser DL, Soslowsky LJ. Restoration of 
anterior -posterior rotator cuff force balance improves shoulder function in a rat model 
of chronic massive tears. J Orthop Res. 2011 Jul; 29(7):1028 -33.  
Jost B, Zumstein M, Pfirrmann CW, Gerber C. Long -term outcome after structual failure of 
rotator cuff repairs. J Bone Joint Surg Am. 2006; 88(3):472 -9. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 70 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Kirkley A, Griffin S, Alvarez C. The development and evaluation of a disease -specific quality 
of life measurement tool for rotator cuff disease: The Western O ntario Rotator Cuff 
Index (WORC). Clin J Sports Med. 2003;13:84 -92. 
Lehman C, Cuomo F, Kummer FJ, Zuckerman JD. The incidence of full thickness rotator cuff 
tears in a large cadaveric population. Bull Hosp Jt Dis 1995; 54(1):30 -1. 
Liu X, Manzano G, Kim HT,  Feeley BT. A rat model of massive rotator cuff tears. J Orthop 
Res. 2011;29:588 -95 
Loew M, Raiss P. A symptom -based classification for shoulders with massive rotator cuff 
defects. Int Orthop. 2010 Feb;34(1):63 -9. 
Matava MJ, Purcell DB, Rudzki JR. Partial -thickness rotator cuff tears. Am J Sports Med 2005 
Sept; 33(9):1405 -17. 
Matthews TJ, Hand GC, Rees JL, Athanasou NA, Carr AJ. Pathology of the torn rotator cuff 
tendon. J Bone Joint Surg Br 2006 Apr;88(4):489 -495. 
Mellado JM, Calmet J, Olona M, Esteve C, C amins A, Pérez Del Palomar L, Giné J, Sauri A. 
Surgically repaired massive rotator cuff tears: MRI of tendon integrity, muscle fatty 
degeneration, and muscle fatty degeneration, and muscle atrophy correlated with 
intraoperative and clinical findings. AJR A m J Roentgenol 2005 May;184(5):1456 -63. 
Mehta, CR, Pocock, SJ. Adaptive increase in sample size when interim results are promising: 
A practical guide with examples.  Statist. Med. 2000; 00:1 –6. 
Michener LA, McClure PW, Sennett BJ. American Shoulder and Elb ow Surgeons 
Standardized Shoulder Assessment Form, patient self -report section: Reliability, 
validity, and responsiveness. J Shoulder Elbow Surg 2002, 11(6):587 -94. 
Moser M, Jablonski MV, Horodyski M, Wright TW, Functional outcome of surgically treated 
massive rotator cuff tears: a comparison of complete repair, partial repair and 
debridement. Orthopedics 2007;30:479 -82. 
Mulieri P, Dunning P, Klein S, Pupello D, Frankle M. Reverse shoulder arthroplasty for the 
treatment of irreparable rotator cuff tear with out glenohumeral arthritis. J Bone Joint 
Surg Br. 2010; 92:2544 -56. 
Reilly P, Macleod I, Macfarlane R, Windley J, Emery RJ. Dead men and radiologists don't lie: 
a review of cadaveric and radiological studies of rotator cuff tear prevalence. Ann R 
Coll Surg  Engl 2006 Mar;88(2):116 -21. 
Richards RR, An K -N, Bigliani LU, Friedman RJ, Gartsman GM, Gristina AG, Iannotti JP, 
Mow VC, Sidles JA, Zuckerman JD. A standardized method for the assessment of 
shoulder function. J Shoulder Elbow Surg. 1994;3:347 -52. 
Senekov ic V, Poberaj B, Kovacic L, Mikek M, Adar D, Dekel A. Prospective clinical study of 
a novel biodegradable sub -acromial spacer in treatment of massive irreparable rotator 
cuff tears. Eur J Orthop Surg Traumatol. 2013 Apr;23(3):311 -6. 
The EuroQoL Group. Euro -Qol-a new facility for the measurement of health -related quality of 
life. Health Policy 1990;16(3):199 -208. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 71 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
 Senekovic V, Poberaj B, Kovacic L, Mikek M,Adar E, Dekel A, Prospective clinical study of a 
novel biodegradable sub -acromial spacer in treatment of  massive irreparable rotator 
cuff tears. Eur J Orthop Surg Traumatol 2013:(23):311 -316 
Tonino PM, Gerber C, Itoi E, Porcellini G, Sonnabend D, Walch G. Complex shoulder 
disorders: evaluation and treatment. J Am Acad Orthop Surg 2009;17: 125 -36 
Vistosky JL,  Basamania C, Seebauer L, Rockwood CA, Jensen KL. Cuff tear arthropathy: 
pathogenesis, classification and algorithm for treatment. J Bone Joint Surg Am 
2004;86(Suppl 2):35 -40 
Walch G, Edwards TB, Boulahia A, Nové -Josserand L, Neyton L, Szabo I. Arthroscopi c 
tenotomy of the long head of the biceps in the treatment of rotator cuff tears: clinical 
and radiographic results of 307 case.  J Shoulder Elbow Surg 2005;14(3):238 -46. 
Wessel J, Razmjou H, Mewa Y, Holtby R.  The factor validity of the Western Ontario Ro tator 
Cuff Index. BMC Musculoskeletal Disord 2005 May 4;6:22.  
Yamaguchi K, Ditsios K, Middleton WD, Hildenbolt CF, Galatz LM, Teefey SA. The 
demographic and morphological features of rotator cuff. A comparison of 
asymptomatic and symptomatic shoulders. J B one Joint Surg Am 2006 
Aug;88(8):1699 -704. 
Ortho -Space Ltd: CLD -OR-010 
 
CONFIDENTIAL  
THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIE TARY AND  
MAY NOT BE COPIED IN ANY MANNER WITHOUT WRITTEN PERMISSION OF ORTHOSPACE LTD.  
Page 72 of 137                                                                                    CIP Version 4.0 March 26 , 201 8  
 
  